<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="THALOMID">
  <Text>
    <Section id="S1" name="adverse reactions">  6 ADVERSE REACTIONS

  The following adverse reactions are described in detail in other labeling sections:

 *  Teratogenicity [see  Boxed Warning  ,  Warnings and Precautions (5.1  ,  5.2)  , and  Patient Counseling Information (17)  ]  
 *  Venous and Arterial Thromboembolism [see  Boxed Warning  ,  Warnings and Precautions (5.3)  , and  Patient Counseling Information (17)  ]  
 *  Increased Mortality in Patients with MM When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone [see  Warnings and Precautions (5.4)  ]  
 *  Drowsiness and Somnolence [see  Warnings and Precautions (5.5)  ]  
 *  Peripheral Neuropathy [see  Warnings and Precautions (5.6)  ]  
 *  Dizziness and Orthostatic Hypotension [see  Warnings and Precautions (5.7)  ]  
 *  Neutropenia [see  Warnings and Precautions (5.8)  ]  
 *  Thrombocytopenia [see  Warnings and Precautions (5.9)  ]  
 *  Increased HIV Viral Load [see  Warnings and Precautions (5.10)  ]  
 *  Bradycardia [see  Warnings and Precautions (5.11)  ]  
 *  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis [see  Warnings and Precautions (5.12)  ]  
 *  Seizures [see  Warnings and Precautions (5.13)  ]  
 *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.14)  ]  
 *  Hypersensitivity [see  Warnings and Precautions (5.16)  ]  
   *  MM: The most common adverse reactions (&gt;= 20%) are fatigue, hypocalcemia, edema, constipation, neuropathy-sensory, dyspnea, muscle weakness, leukopenia, neutropenia, rash/desquamation, confusion, anorexia, nausea, anxiety/agitation, asthenia, tremor, fever, weight loss, thrombosis/embolism, neuropathy-motor, weight gain, dizziness, and dry skin. (  6.1  ) 
 *  ENL: The most common adverse reactions (&gt;= 10%) are somnolence, rash, and headache. (  6.1  ) 
      EXCERPT:     To report SUSPECTED ADVERSE REACTIONS or embryo-fetal exposure: contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  
 

 

  6.1 Clinical Trials Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

 Most patients taking thalidomide can be expected to experience adverse reactions.

   Teratogenicity:  

 The most serious toxicity associated with thalidomide is its documented human teratogenicity. The risk of severe birth defects, primarily phocomelia or death to the fetus, is extremely high during the critical period of pregnancy. The critical period is estimated, depending on the source of information, to range from 35 to 50 days after the last menstrual period. The risk of other potentially severe birth defects outside this critical period is unknown, but may be significant. Based on present knowledge, thalidomide must not be used at any time during pregnancy.

 Because thalidomide is present in the semen of patients receiving the drug, males receiving thalidomide must always use a latex or synthetic condom during any sexual contact with females of reproductive potential, even if he has undergone a successful vasectomy.

   Venous and Arterial Thromboembolism:  

 An increased risk of venous thromboembolism (such as deep vein thrombosis and pulmonary embolism), ischemic heart disease (including myocardial infarction), and stroke have been reported in patients with multiple myeloma treated with thalidomide  [see  Warnings and Precautions (5.3)  ]  .

   Peripheral Neuropathy:  

 Peripheral neuropathy is a very common, potentially severe, adverse reaction of treatment with thalidomide that may result in irreversible damage.  Peripheral neuropathy generally occurs following chronic use over a period of months. However, reports following relatively short-term use also exist. Incidence of neuropathy events leading to discontinuation, dose reduction or interruption increases with cumulative dose and duration of therapy.  Symptoms may occur some time after thalidomide treatment has been stopped and may resolve slowly or not at all.

 Somnolence, dizziness, and rash are the most commonly observed adverse reactions associated with the use of thalidomide. Adverse event profiles from clinical trials are summarized in the sections that follow.

   Adverse Reactions in Multiple Myeloma Controlled Clinical Trials  

 The safety analyses were conducted in two controlled clinical studies (Study 1 and Study 2).  The safety analysis in Study 1 was conducted on 204 patients who received treatment.  Table 1  lists the most common adverse drug reactions (&gt;= 10%). The most frequently reported adverse reactions were fatigue, hypocalcemia, edema, constipation, sensory neuropathy, dyspnea, muscle weakness, leukopenia, neutropenia, rash/desquamation, confusion, anorexia, nausea, anxiety/agitation, tremor, fever, weight loss, thrombosis/embolism, neuropathy-motor, weight gain, dizziness, and dry skin.

 Twenty-three percent of patients (47/204) discontinued due to adverse reactions; 30% (31/102) from the THALOMID/dexamethasone arm and 16% (16/102) from the dexamethasone alone arm.

 Table 1: Adverse Drug Reactions Reported in &gt;=10% of Patients in the THALOMID/Dexamethasone Arm (Study 1 - Safety Population; N=204) 
 *Treatment-emergent adverse reactions reported in &gt;=10% of  patients in THALOMID/dexamethasone arm and with a &gt;=1% difference in the THALOMID/dexamethasone arm compared to the dexamethasone alone arm.   
  
   Body SystemAdverse Reaction      Thal + Dex *(N=102)                                   Dex Alone*(N=102)                                    
   All Gradesn (%)            Grade 3/4n (%)             All Gradesn (%)            Grade 3/4n (%)            
   Metabolic/Laboratory     97 (95)                    33 (32)                    96 (94)                    30 (29)                     
       Hypocalcemia         73 (72)                    11 (11)                    60 (59)                    5 (5)                       
   Neurology                92 (90)                    30 (29)                    76 (74)                    18 (18)                     
       Neuropathy-sensory   55 (54)                    4 (4)                      28 (28)                    1 (1)                       
       Confusion            29 (28)                    9 (9)                      12 (12)                    3 (3)                       
       Anxiety/agitation    26 (26)                    1 (1)                      14 (14)                    3 (3)                       
       Tremor               26 (26)                    1 (1)                      6 (6)                      0 (0)                       
       Neuropathy-motor     22 (22)                    8 (8)                      16 (16)                    5 (5)                       
       Dizziness/      lightheadedness  20 (20)                    1 (1)                      14 (14)                    0 (0)                       
       Depressed level of      consciousness  16 (16)                    3 (3)                      3 (3)                      3 (3)                       
   Constitutional Symptoms    91 (89)                    19 (19)                    84 (82)                    16 (16)                     
       Fatigue              81 (79)                    17 (17)                    72 (71)                    13 (13)                     
       Fever                24 (24)                    1 (1)                      20 (20)                    3 (3)                       
       Weight loss          23 (23)                    1 (1)                      21 (21)                    2 (2)                       
       Weight gain          22 (22)                    1 (1)                      13 (13)                    0 (0)                       
   Blood/Bone Marrow        88 (86)                    29 (29)                    96 (94)                    19 (19)                     
       Leukocytes (decreased)  36 (35)                    6 (6)                      30 (29)                    3 (3)                       
       Neutrophils (decreased)  32 (31)                    10 (10)                    24 (24)                    10 (10)                     
   Gastrointestinal         83 (81)                    22 (22)                    70 (69)                    8 (8)                       
       Constipation         56 (55)                    8 (8)                      29 (28)                    1 (1)                       
       Anorexia             29 (28)                    4 (4)                      25 (24)                    2 (2)                       
       Nausea               29 (28)                    5 (5)                      23 (22)                    1 (1)                       
       Mouth dryness        12 (12)                    1 (1)                      6 (6)                      0 (0)                       
   Cardiovascular           70 (69)                    37 (36)                    60 (59)                    21 (21)                     
       Edema                58 (56)                    6 (6)                      47 (46)                    4 (4)                       
       Thrombosis/embolism  23 (22)                    21 (21)                    5 (5)                      5 (5)                       
   Pain                     64 (63)                    10 (10)                    66 (65)                    15 (15)                     
       Myalgia              17 (17)                    0 (0)                      14 (14)                    1 (1)                       
       Arthralgia           13 (13)                    0 (0)                      10 (10)                    2 (2)                       
   Pulmonary                52 (51)                    19 (19)                    51 (50)                    20 (20)                     
       Dyspnea              43 (42)                    13 (13)                    32 (31)                    15 (15)                     
   Dermatology/Skin         48 (47)                    5 (5)                      35 (34)                    2 (2)                       
       Rash/desquamation    31 (30)                    4 (4)                      18 (18)                    2 (2)                       
       Dry skin             21 (21)                    0 (0)                      11 (11)                    0 (0)                       
   Hepatic                  47 (46)                    7 (7)                      45 (44)                    4 (4)                       
       Bilirubin            14 (14)                    2 (2)                      10 (10)                    2 (2)                       
   Musculoskeletal          42 (41)                    9 (9)                      41 (40)                    14 (14)                     
       Muscle weakness      41 (40)                    6 (6)                      38 (37)                    13 (13)                     
      The safety analysis in Study 2 was conducted on 466 patients who received treatment.  Table 2  lists the most common adverse drug reactions (&gt;= 10%) that were observed.  Table 3  lists the most common Grade 3/4 adverse drug reactions (occurring at &gt; 2%) that were observed. The adverse reactions most often reported by patients treated with THALOMID/dexamethasone were constipation, peripheral edema, tremor, asthenia, dizziness and fatigue. Adverse reactions with a frequency at least 2-fold higher in the THALOMID/dexamethasone group than in the placebo/dexamethasone group include constipation, tremor, deep vein thrombosis and peripheral sensory neuropathy.
 

 Twenty-six percent of patients (121/466) discontinued due to adverse events; 37% (86/234) from the THALOMID/dexamethasone arm and 15% (35/232) from the placebo/dexamethasone arm.

 Table 2: Adverse Drug Reactions Reported in &gt;=10% of Patients in the THALOMID/Dexamethasone Arm (Study 2 - Safety Population; N=466) 
  *All adverse reactions reported in &gt;=10% of patients in THALOMID/dexamethasone arm and with a &gt;=1% difference in proportion of patients between the THALOMID/dexamethasone arm compared to the placebo/dexamethasone arm.   NOS = not otherwise specified.    
  
   Body SystemAdverse Reaction      Thal/Dex (N=234)*n (%)      Placebo/Dex (N=232)*n (%)     
   Patients with at least 1 Adverse Reaction      233 (99)                   230 (99)                  
   General Disorders and Administration Site Conditions      176 (75)                   149 (64)                  
       Edema peripheral     80 (34)                    57 (25)                     
       Asthenia             56 (24)                    47 (20)                     
       Fatigue              50 (21)                    36 (16)                     
       Edema NOS            31 (13)                    19 (8)                      
   Gastrointestinal Disorders    162 (69)                   149 (64)                    
       Constipation         116 (50)                   49 (21)                     
       Nausea               30 (13)                    27 (12)                     
       Dyspepsia            27 (11)                    21 (9)                      
   Nervous System Disorders    161 (69)                   138 (60)                    
       Tremor               62 (26)                    29 (12)                     
       Dizziness            51 (23)                    32 (14)                     
       Paresthesia          27 (12)                    15 (6)                      
       Peripheral sensory neuropathy  24 (10)                    12 (5)                      
   Infections and Infestations    139 (59)                   138 (60)                    
       Pneumonia NOS        35 (15)                    28 (12)                     
   Psychiatric Disorders    90 (38)                    97 (42)                     
       Anxiety              27 (12)                    22 (10)                     
       Depression           24 (10)                    19 (8)                      
   Metabolism and Nutrition Disorders    96 (41)                    89 (38)                     
       Hyperglycemia NOS    36 (15)                    32 (14)                     
   Vascular Disorders       92 (39)                    53 (23)                     
       Deep vein thrombosis  30 (13)                    4 (2)                       
     Table 3: Grade 3/4 Adverse Drug Reactions Reported in &gt;2% of Patients in the THALOMID/Dexamethasone Arm (Study 2 - Safety Population; N=466) 
  *All Grade 3/4 adverse reactions with &gt;2% of patients in THALOMID/dexamethasone arm and with a higher frequency in the THALOMID/dexamethasone arm compared to the placebo/dexamethasone arm.   NOS = not otherwise specified.    
  
   Body SystemAdverse Reaction      THALOMID/Dex (N=234)*n (%)      Placebo/Dex (N=232)*n (%)     
   Infections and Infestations      50 (21)                    36 (16)                   
       Pneumonia NOS        17 (7)                     14 (6)                      
       Bronchopneumonia NOS  7 (3)                      3 (1)                       
   General Disorders andAdministration Site Conditions      44 (19)                    26 (11)                   
       Asthenia             11 (5)                     4 (2)                       
   Metabolism and NutritionDisorders      33 (14)                    34 (15)                   
       Hypokalemia          7 (3)                      3 (1)                       
   Nervous System Disorders      47 (20)                    20 (9)                    
       Syncope              8 (3)                      1 (&lt;1)                      
       Peripheral neuropathy NOS  8 (3)                      0 (0)                       
       Cerebrovascular accident  6 (3)                      1 (&lt;1)                      
   Cardiac Disorders          35 (15)                    27 (11)                   
       Atrial fibrillation  11 (5)                     8 (3)                       
       Myocardial ischemia  6 (3)                      2 (1)                       
   Vascular Disorders         42 (18)                    14 (6)                    
       Deep vein thrombosis  27 (12)                    4 (2)                       
   Gastrointestinal Disorders      26 (11)                    22 (10)                   
       Constipation         7 (3)                      2 (1)                       
   Investigations             21 (9)                     21 (9)                    
       Weight increased     8 (3)                      4 (2)                       
   Blood and Lymphatic SystemDisorders      24 (10)                    17 (7)                    
       Neutropenia          8 (3)                      6 (3)                       
   Respiratory, Thoracic, andMediastinal Disorders      27 (12)                    13 (6)                    
       Pulmonary embolism   16 (7)                     4 (2)                       
   Psychiatric Disorders      19 (8)                     8 (3)                     
       Anxiety              5 (2)                      3 (1)                       
       Confusional state    5 (2)                      2 (1)                       
   Ear and Labyrinth Disorders      6 (3)                      0 (0)                     
       Vertigo              5 (2)                      0 (0)                       
        Less Common Adverse Drug Reactions in Multiple Myeloma Controlled Clinical Trials  
 

 In Study 2, THALOMID in combination with dexamethasone in patients with multiple myeloma, the following adverse drug reactions not described above were reported*:

   Gastrointestinal disorders:  Vomiting NOS, dry mouth, peritonitis, diverticular perforation

   Nervous system disorders:  Somnolence, hypoesthesia, polyneuropathy NOS, transient ischemic attack

   Respiratory, thoracic, and mediastinal disorders:  Bronchitis NOS

   Psychiatric disorders:  Mood alteration NOS

   Vascular disorders:  Hypotension NOS, orthostatic hypotension

   Cardiac disorders:  Bradycardia NOS

   Eye disorders:  Blurred vision

 * All adverse reactions with &gt;=3% of patients in THALOMID/dexamethasone arm and with a &gt;=1% difference in proportion of patients between the THALOMID/dexamethasone arm compared to the placebo/dexamethasone arm. All grade 3/4 and serious adverse reactions reported &gt;2 patients in THALOMID/dexamethasone arm and with a percentage higher in the THALOMID/dexamethasone arm compared to the placebo/dexamethasone arm have been considered for possible inclusion. In any cases medical judgment has been applied for consideration of causality assessment.

   Adverse Reactions in Erythema Nodosum Leprosum (ENL) Clinical Trials  

   Table 4  lists treatment-emergent signs and symptoms that occurred in THALOMID-treated patients in clinical trials in ENL. The most common adverse reactions (&gt;=10%) reported in patients with ENL were somnolence, rash, headache. Doses ranged from 50 to 300 mg/day. All adverse reactions were mild to moderate in severity, and none resulted in discontinuation.

 Table 4: Summary of Adverse Events (AEs) Reported in Celgene-sponsored Controlled Clinical Trials 
   Body System/Adverse Event      All AEs Reportedin Patients with ENL      AEs Reported in &gt;=3 HIV-seropositive Patients     
                                                         Thalidomide                Placebo                   
                              50 to 300 mg/day(N=24)      100 mg/day(N=36)           200 mg/day(N=32)           (N=35)                    
 Blood and Lymphatic          0                          8 (22.2%)                  13 (40.6%)                 10 (28.6%)                
        Anemia              0                          2 (5.6%)                   4 (12.5%)                  3 (8.6%)                    
        Leukopenia          0                          6 (16.7%)                  8 (25.0%)                  3 (8.6%)                    
        Lymphadenopathy     0                          2 (5.6%)                   4 (12.5%)                  3 (8.6%)                    
   Body as a Whole            16 (66.7%)                 18 (50.0%)                 19 (59.4%)                 13 (37.1%)                
        Abdominal pain      1 (4.2%)                   1 (2.8%)                   1 (3.1%)                   4 (11.4%)                   
        Accidental injury   1 (4.2%)                   2 (5.6%)                   0                          1 (2.9%)                    
        Asthenia            2 (8.3%)                   2 (5.6%)                   7 (21.9%)                  1 (2.9%)                    
        Back pain           1 (4.2%)                   2 (5.6%)                   0                          0                           
        Chills              1 (4.2%)                   0                          3 (9.4%)                   4 (11.4%)                   
        Facial edema        1 (4.2%)                   0                          0                          0                           
        Fever               0                          7 (19.4%)                  7 (21.9%)                  6 (17.1%)                   
        Headache            3 (12.5%)                  6 (16.7%)                  6 (18.7%)                  4 (11.4%)                   
        Infection           0                          3 (8.3%)                   2 (6.3%)                   1 (2.9%)                    
        Malaise             2 (8.3%)                   0                          0                          0                           
        Neck pain           1 (4.2%)                   0                          0                          0                           
        Neck rigidity       1 (4.2%)                   0                          0                          0                           
        Pain                2 (8.3%)                   0                          1 (3.1%)                   2 (5.7%)                    
   Digestive System           5 (20.8%)                  16 (44.4%)                 16 (50.0%)                 15 (42.9%)                
        Anorexia            0                          1 (2.8%)                   3 (9.4%)                   2 (5.7%)                    
        Constipation        1 (4.2%)                   1 (2.8%)                   3 (9.4%)                   0                           
        Diarrhea            1 (4.2%)                   4 (11.1%)                  6 (18.7%)                  6 (17.1%)                   
        Dry mouth           0                          3 (8.3%)                   3 (9.4%)                   2 (5.7%)                    
        Flatulence          0                          3 (8.3%)                   0                          2 (5.7%)                    
        Liver function tests            multiple abnormalities  0                          0                          3 (9.4%)                   0                           
        Nausea              1 (4.2%)                   0                          4 (12.5%)                  1 (2.9%)                    
        Oral moniliasis     1 (4.2%)                   4 (11.1%)                  2 (6.3%)                   0                           
        Tooth pain          1 (4.2%)                   0                          0                          0                           
   Metabolic and Endocrine Disorders      1 (4.2%)                   8 (22.2%)                  12 (37.5%)                 8 (22.9%)                 
        Edema peripheral    1 (4.2%)                   3 (8.3%)                   1 (3.1%)                   0                           
        Hyperlipemia        0                          2 (5.6%)                   3 (9.4%)                   1 (2.9%)                    
        SGOT increased      0                          1 (2.8%)                   4 (12.5%)                  2 (5.7%)                    
   Nervous System             13 (54.2%)                 19 (52.8%)                 18 (56.3%)                 12 (34.3%)                
        Agitation           0                          0                          3 (9.4%)                   0                           
        Dizziness           1 (4.2%)                   7 (19.4%)                  6 (18.7%)                  0                           
        Insomnia            0                          0                          3 (9.4%)                   2 (5.7%)                    
        Nervousness         0                          1 (2.8%)                   3 (9.4%)                   0                           
        Neuropathy          0                          3 (8.3%)                   0                          0                           
        Paresthesia         0                          2 (5.6%)                   5 (15.6%)                  4 (11.4%)                   
        Somnolence          9 (37.5%)                  13 (36.1%)                 12 (37.5%)                 4 (11.4%)                   
        Tremor              1 (4.2%)                   0                          0                          0                           
        Vertigo             2 (8.3%)                   0                          0                          0                           
   Respiratory System         3 (12.5%)                  9 (25.0%)                  6 (18.7%)                  9 (25.7%)                 
        Pharyngitis         1 (4.2%)                   3 (8.3%)                   2 (6.3%)                   2 (5.7%)                    
        Rhinitis            1 (4.2%)                   0                          0                          4 (11.4%)                   
        Sinusitis           1 (4.2%)                   3 (8.3%)                   1 (3.1%)                   2 (5.7%)                    
   Skin and Appendages        10 (41.7%)                 17 (47.2%)                 18 (56.3%)                 19 (54.3%)                
        Acne                0                          4 (11.1%)                  1 (3.1%)                   0                           
        Dermatitis fungal   1 (4.2%)                   2 (5.6%)                   3 (9.4%)                   0                           
        Nail disorder       1 (4.2%)                   0                          1 (3.1%)                   0                           
        Pruritus            2 (8.3%)                   1 (2.8%)                   2 (6.3%)                   2 (5.7%)                    
        Rash                5 (20.8%)                  9 (25.0%)                  8 (25.0%)                  11 (31.4%)                  
        Rash maculopapular  1 (4.2%)                   6 (16.7%)                  6 (18.7%)                  2 (5.7%)                    
        Sweating            0                          0                          4 (12.5%)                  4 (11.4%)                   
   Urogenital System          2 (8.3%)                   6 (16.7%)                  2 (6.3%)                   4 (11.4%)                 
        Albuminuria         0                          3 (8.3%)                   1 (3.1%)                   2 (5.7%)                    
        Hematuria           0                          4 (11.1%)                  0                          1 (2.9%)                    
        Impotence           2 (8.3%)                   1 (2.8%)                   0                          0                           
        Other Adverse Events Observed in ENL Patients  
 

 THALOMID in doses up to 400 mg/day has been administered investigationally in the United States over a 19-year period in 1465 patients with ENL. The published literature describes the treatment of an additional 1678 patients. To provide a meaningful estimate of the proportion of the individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using a modified COSTART dictionary/terminology. These categories are used in the listing below. All reported events are included except those already listed in the previous table. Due to the fact that these data were collected from uncontrolled studies, the incidence rate cannot be determined. No causal relationship between THALOMID and these events can be conclusively determined at this time. These are reports of all adverse events noted by investigators in patients to whom they had administered thalidomide.

   Blood and Lymphatic:  ESR decrease, eosinophilia, granulocytopenia, hypochromic anemia, leukemia, leukocytosis, leukopenia, MCV elevated, RBC abnormal, spleen palpable, thrombocytopenia.

   Body as a Whole:  Abdomen enlarged, fever, photosensitivity, upper extremity pain.

   Cardiovascular System:  Bradycardia, hypertension, hypotension, peripheral vascular disorder, tachycardia, vasodilation.

   Digestive System:  Anorexia, appetite increase/weight gain, dry mouth, dyspepsia, enlarged liver, eructation, flatulence, increased liver function tests, intestinal obstruction, vomiting.

   Metabolic and Endocrine:  ADH inappropriate, amyloidosis, bilirubinemia, BUN increased, creatinine increased, cyanosis, diabetes, edema, electrolyte abnormalities, hyperglycemia, hyperkalemia, hyperuricemia, hypocalcemia, hypoproteinemia, LDH increased, phosphorus decreased, SGPT increased.

   Muscular Skeletal:  Arthritis, bone tenderness, hypertonia, joint disorder, leg cramps, myalgia, myasthenia, periosteal disorder.

   Nervous System:  Abnormal thinking, agitation, amnesia, anxiety, causalgia, circumoral paresthesia, confusion, depression, euphoria, hyperesthesia, insomnia, nervousness, neuralgia, neuritis, neuropathy, paresthesia, peripheral neuritis, psychosis.

   Respiratory System:  Cough, emphysema, epistaxis, pulmonary embolus, rales, upper respiratory infection, voice alteration.

   Skin and Appendages:  Acne, alopecia, dry skin, eczematous rash, exfoliative dermatitis, ichthyosis, perifollicular thickening, skin necrosis, seborrhea, sweating, urticaria, vesiculobullous rash.

   Special Senses:  Amblyopia, deafness, dry eye, eye pain, tinnitus.

   Urogenital:  Decreased creatinine clearance, hematuria, orchitis, proteinuria, pyuria, urinary frequency.

   Other Adverse Events Observed in HIV-seropositive Patients  

 In addition to controlled clinical trials, THALOMID has been used in uncontrolled studies in 145 patients. Less frequent adverse events that have been reported in these HIV-seropositive patients treated with THALOMID were grouped into a smaller number of standardized categories using modified COSTART dictionary/terminology and these categories are used in the listing below. Adverse events that have already been included in the tables and narrative above, or that are too general to be informative are not listed.

   Blood and Lymphatic:  Aplastic anemia, macrocytic anemia, megaloblastic anemia, microcytic anemia.

   Body as a Whole:  Ascites, AIDS, allergic reaction, cellulitis, chest pain, chills and fever, cyst, decreased CD4 count, facial edema, flu syndrome, hernia, thyroid hormone level altered, moniliasis, photosensitivity reaction, sarcoma, sepsis, viral infection.

   Cardiovascular System:  Angina pectoris, arrhythmia, atrial fibrillation, bradycardia, cerebral ischemia, cerebrovascular accident, congestive heart failure, deep thrombophlebitis, heart arrest, heart failure, hypertension, hypotension, murmur, myocardial infarct, palpitation, pericarditis, peripheral vascular disorder, postural hypotension, syncope, tachycardia, thrombophlebitis, thrombosis.

   Digestive System:  Cholangitis, cholestatic jaundice, colitis, dyspepsia, dysphagia, esophagitis, gastroenteritis, gastrointestinal disorder, gastrointestinal hemorrhage, gum disorder, hepatitis, pancreatitis, parotid gland enlargement, periodontitis, stomatitis, tongue discoloration, tooth disorder.

   Metabolic and Endocrine:  Avitaminosis, bilirubinemia, dehydration, hypercholesterolemia, hypoglycemia, increased alkaline phosphatase, increased lipase, increased serum creatinine, peripheral edema.

   Muscular Skeletal:  Myalgia, myasthenia.

   Nervous System:  Abnormal gait, ataxia, decreased libido, decreased reflexes, dementia, dysesthesia, dyskinesia, emotional lability, hostility, hypalgesia, hyperkinesia, incoordination, meningitis, neurologic disorder, tremor, vertigo.

   Respiratory System:  Apnea, bronchitis, lung disorder, lung edema, pneumonia (including Pneumocystis carinii pneumonia), rhinitis.

   Skin and Appendages:  Angioedema, benign skin neoplasm, eczema, herpes simplex, incomplete Stevens-Johnson syndrome, nail disorder, pruritus, psoriasis, skin discoloration, skin disorder.

   Special Senses:  Conjunctivitis, eye disorder, lacrimation disorder, retinitis, taste perversion.

   6.2 Postmarketing Experience

  The following additional adverse reactions have been identified during post approval use of THALOMID and are not already included in Clinical Trials Experience  [see  Adverse Reactions (6.1)  ]  . Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

   Blood and Lymphatic:  Decreased white blood cell counts including febrile neutropenia, changes in prothrombin time, pancytopenia, chronic myelogenous leukemia, nodular sclerosing Hodgkin's disease, erythroleukemia, lymphedema, lymphopenia.

   Body as a Whole:  Hangover effect

   Cardiovascular System:  Sick sinus syndrome, EKG abnormalities, pulmonary hypertension.

   Digestive System:  Intestinal perforation, gastrointestinal perforations, bile duct obstruction, stomach ulcer, aphthous, stomatitis.

   Ear and Labyrinthine Disorders:  Hearing impairment.

   Immune System Disorders:  Hypersensitivity.

   Infections and infestations:  Severe infections (e.g., fatal sepsis including septic shock) and viral infections (including varicella zoster virus, cytomegalovirus, and hepatitis B virus reactivation).

   Metabolic and Endocrine:  Electrolyte imbalance including hypercalcemia, hyponatremia and hypomagnesemia, hypothyroidism, increased alkaline phosphatase, tumor lysis syndrome, myxedema.

   Nervous System:  Changes in mental status or mood including suicide attempts, disturbances in consciousness including lethargy, loss of consciousness or stupor, seizures including grand mal convulsions and status epilepticus, Parkinson's disease, stroke, carpal tunnel, Raynaud's syndrome, migraine, foot drop.

   Renal and Urinary Disorders:  Renal failure, acute renal failure, oliguria, enuresis.

   Reproductive System and Breast Disorders:  amenorrhea, sexual dysfunction, galactorrhea, gynecomastia, metrorrhagia.

   Respiratory System:  Pleural effusion, interstitial lung disease.

   Skin and Appendages:  Erythema multiforme, erythema nodosum, toxic epidermal necrolysis, purpura, petechiae.

   Special Senses:  Diplopia, nystagmus

</Section>
    <Section id="S2" name="boxed warnings">

    BOXED WARNING: 

    WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM  

   EMBRYO-FETAL TOXICITY  

   If thalidomide is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. Thalidomide should never be used by females who are pregnant or who could become pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects.  

   Because of this toxicity and in an effort to make the chance of embryo-fetal exposure to THALOMID  (r)   (thalidomide) as negligible as possible, THALOMID  (r)   (thalidomide) is approved for marketing only through a special restricted distribution program: THALOMID REMS  (r)   program, approved by the Food and Drug Administration.  

   You can get the information about THALOMID and the THALOMID REMS program on the Internet at www.celgeneriskmanagement.com or by calling the manufacturer's toll-free number 1-888-423-5436.  

   VENOUS THROMBOEMBOLISM  

   The use of THALOMID  (r)   (thalidomide) in multiple myeloma results in an increased risk of venous thromboembolism, such as deep venous thrombosis and pulmonary embolism.  This risk increases significantly when thalidomide is used in combination with standard chemotherapeutic agents including dexamethasone. In one controlled trial, the rate of venous thromboembolism was 22.5% in patients receiving thalidomide in combination with dexamethasone compared to 4.9% in patients receiving dexamethasone alone (p = 0.002). Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Instruct patients to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Consider thromboprophylaxis based on an assessment of individual patients' underlying risk factors.  

   EXCERPT:     WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM  

     See full prescribing information for complete boxed warning.    

   EMBRYO-FETAL TOXICITY  

 *  If thalidomide is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. Thalidomide should never be used by females who are pregnant or who could be pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. 
 *  Pregnancy must be excluded before start of treatment. Prevent pregnancy thereafter by the use of two reliable methods of contraception. (5.1, 8.3) 
      THALOMID  (r)   (thalidomide) is only available through a restricted distribution program, the THALOMID REMS  (r)   program (  5.2  ).  
 

   VENOUS THROMBOEMBOLISM  

 *  Significant increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma receiving THALOMID(r) (thalidomide) with dexamethasone (5.3). 
    

</Section>
    <Section id="S3" name="warnings and precautions">   5 WARNINGS AND PRECAUTIONS

   EXCERPT:    *  Ischemic heart disease (including myocardial infarction) and stroke have been observed in patients treated with THALOMID in combination with dexamethasone. (  5.3  ) 
 *  Increased Mortality: Observed in patients with MM when pembrolizumab was added to dexamethasone and a thalidomide analogue. (  5.4  ) 
 *  Drowsiness and Somnolence: Instruct patients to avoid situations where drowsiness may be a problem and not to take other medications that may cause drowsiness. (  5.5  ) 
 *  Peripheral Neuropathy: Examine patients at monthly intervals for the first 3 months of thalidomide therapy and periodically thereafter for signs or symptoms of peripheral neuropathy. Consider electrophysiological testing, consisting of measurement of sensory nerve action potential (SNAP) amplitudes at baseline and thereafter every 6 months in an effort to detect asymptomatic neuropathy. (  5.6  ) 
 *  Dizziness and Orthostatic Hypotension: Advise patients to sit upright for a few minutes prior to standing up from a recumbent position. (  5.7  ) 
 *  Neutropenia: Patients may require dose interruption and/or dose reduction. (  5.8  ) 
 *  Thrombocytopenia: Patients may require dose interruption and/or dose reduction. (  5.9  ) 
 *  Increased HIV Viral Load: Measure viral load after the first and third months of treatment and every 3 months thereafter. (  5.10  ) 
 *  Bradycardia: Monitor patients for bradycardia and possible syncope. Dose reduction or discontinuation may be required. (  5.11  ) 
 *  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Do not resume THALOMID following discontinuation for these reactions. (  5.12  ) 
 *  Seizures: Monitor patients with a history of seizures or at risk for the development of seizures closely for clinical changes that could precipitate acute seizure activity. (  5.13  ) 
 *  Tumor Lysis Syndrome: Monitor patients at risk (e.g., those with high tumor burden prior to treatment) and take appropriate precautions. (  5.14  ) 
 *  Hypersensitivity: Monitor patients for potential hypersensitivity to the drug and its components. (  5.16  ) 
    
 

   5.1 Embryo-Fetal Toxicity

  Thalidomide is a powerful human teratogen that induces a high frequency of severe and life-threatening birth defects, even after a single dose. Mortality at or shortly after birth has been reported in about 40% of infants. When there is no satisfactory alternative treatment, females of reproductive potential may be treated with thalidomide provided adequate precautions are taken to avoid pregnancy. THALOMID  (r)  (thalidomide) is only available through the THALOMID REMS program [see  Warnings and Precautions (5.2)  ]  .

 Oral ingestion is the only type of maternal thalidomide exposure known to result in drug-associated birth defects. There are no specific data available regarding the reproductive risks of cutaneous absorption or inhalation of thalidomide; however, females of reproductive potential should avoid contact with THALOMID  (r)  (thalidomide) Capsules.  THALOMID Capsules should be stored in blister packs until ingestion. If there is contact with non-intact thalidomide capsules or the powder contents, the exposed area should be washed with soap and water.

 If healthcare providers or other care givers are exposed to body fluids from patients receiving THALOMID (thalidomide) the exposed area should be washed with soap and water.  Appropriate precautions should be utilized, such as wearing gloves to prevent the potential cutaneous exposure to THALOMID.

   Females of Reproductive Potential    Females of reproductive potential must avoid pregnancy for at least 4 weeks before beginning THALOMID therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy.
 

 Females must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control, beginning 4 weeks prior to initiating treatment with THALOMID, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of THALOMID therapy.

 Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing THALOMID therapy and then weekly during the first month, then monthly thereafter in females with regular menstrual cycles or every 2 weeks in females with irregular menstrual cycles [see  Use in Specific Populations (8.3)  ]  .

   Males    Thalidomide is present in the semen of patients receiving the drug. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking THALOMID and for up to 4 weeks after discontinuing THALOMID, even if they have undergone a successful vasectomy.   Male patients taking THALOMID must not donate sperm [see  Use in Specific Populations (8.3)  ]  .
 

   Blood Donation    Patients must not donate blood during treatment with THALOMID and for 4 weeks following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to THALOMID.
 

    5.2 THALOMID REMS Program

  Because of the embryo-fetal risk [see  Warnings and Precautions (5.1)  ]  , THALOMID is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), the THALOMID REMS  program.

 Required components of the THALOMID REMS  program include the following:

 *  Prescribers must be certified with the THALOMID REMS program by enrolling and complying with the REMS requirements. 
 *  Patients must sign a Patient-Physician Agreement Form and comply with the REMS requirements. In particular, female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements [see  Use in Specific Populations (8.3)  ] and males must comply with contraception requirements [see  Use in Specific Populations (8.3)  ] . 
 *  Pharmacies must be certified with the THALOMID REMS program, must only dispense to patients who are authorized to receive THALOMID and comply with REMS requirements. 
    Further information about the THALOMID REMS  program is available at www.celgeneriskmanagement.com or by telephone at 1-888-423-5436.
 

    5.3 Venous and Arterial Thromboembolism

  The use of THALOMID in patients with MM results in an increased risk of venous thromboembolism, such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when thalidomide is used in combination with standard chemotherapeutic agents including dexamethasone. In one controlled trial, the rate of venous thromboembolism was 22.5% in patients receiving thalidomide in combination with dexamethasone compared to 4.9% in patients receiving dexamethasone alone (p = 0.002).

 Ischemic heart disease (11.1%), including myocardial infarction (1.3%), and stroke (cerebrovascular accident, 2.6%) have also occurred in patients with previously untreated MM treated with THALOMID and dexamethasone compared to placebo and dexamethasone (4.7%, 1.7%, and 0.9%, respectively) in one clinical trial [see  Adverse Reactions (6.1)  ]  .

 Consider thromboprophylaxis based on an assessment of individual patients' underlying risk factors. Patients and physicians should be observant for the signs and symptoms of thromboembolism. Advise patients to seek immediate medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling [see  Boxed Warning  ]  . Agents that also may increase the risk of thromboembolism should be used with caution in patients receiving THALOMID [see  Drug Interactions (7.7)  ]  .

     5.4 Increased Mortality in Patients with MM When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone  

   In two randomized clinical trials in patients with MM, the addition of pembrolizumab to a thalidomide analogue plus dexamethasone, a use for which no PD-1 or PD-L1 blocking antibody is indicated, resulted in increased mortality. Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.  

    5.5 Drowsiness and Somnolence

  Thalidomide frequently causes drowsiness and somnolence. Patients should be instructed to avoid situations where drowsiness may be a problem and not to take other medications that may cause drowsiness without adequate medical advice [see  Drug Interactions (7.1)  ].   Advise patients as to the possible impairment of mental and/or physical abilities required for the performance of hazardous tasks, such as driving a car or operating other complex or dangerous machinery. Dose reductions may be required.

    5.6 Peripheral Neuropathy

  Thalidomide is known to cause nerve damage that may be permanent. Peripheral neuropathy is a common (&gt;=10%) and potentially severe adverse reaction of treatment with thalidomide that may be irreversible. Peripheral neuropathy generally occurs following chronic use over a period of months; however, peripheral neuropathy following relatively short-term use has been reported. The correlation with cumulative dose is unclear. Symptoms may occur some time after thalidomide treatment has been stopped and may resolve slowly or not at all.

 Few reports of neuropathy have arisen in the treatment of ENL despite long-term thalidomide treatment. However, the inability clinically to differentiate thalidomide neuropathy from the neuropathy often seen in Hansen's disease makes it difficult to determine accurately the incidence of thalidomide-related neuropathy in ENL patients treated with thalidomide.

 Patients should be examined at monthly intervals for the first 3 months of thalidomide therapy to enable the clinician to detect early signs of neuropathy, which include numbness, tingling or pain in the hands and feet. Patients should be evaluated periodically thereafter during treatment. Patients should be regularly counseled, questioned, and evaluated for signs or symptoms of peripheral neuropathy. Consideration should be given to electrophysiological testing, consisting of measurement of sensory nerve action potential (SNAP) amplitudes at baseline and thereafter every 6 months in an effort to detect asymptomatic neuropathy. If symptoms of drug-induced neuropathy develop, thalidomide should be discontinued immediately to limit further damage, if clinically appropriate. Usually, treatment with thalidomide should only be reinitiated if the neuropathy returns to baseline status.

 Medications known to be associated with neuropathy should be used with caution in patients receiving thalidomide [see  Drug Interactions (7.3)  ]  .

    5.7 Dizziness and Orthostatic Hypotension

  Patients should also be advised that thalidomide may cause dizziness and orthostatic hypotension and that, therefore, they should sit upright for a few minutes prior to standing up from a recumbent position.

    5.8 Neutropenia

  Decreased white blood cell counts, including neutropenia, have been reported in association with the clinical use of thalidomide. Treatment should not be initiated with an absolute neutrophil count (ANC) of &lt;750/mm  3  . White blood cell count and differential should be monitored on an ongoing basis, especially in patients who may be more prone to neutropenia, such as patients who are HIV-seropositive. If ANC decreases to below 750/mm  3  while on treatment, the patient's medication regimen should be re-evaluated and, if the neutropenia persists, consideration should be given to withholding thalidomide if clinically appropriate.

    5.9 Thrombocytopenia

  Thrombocytopenia, including Grade 3 or 4 occurrences, has been reported in association with the clinical use of thalidomide. Monitor blood counts, including platelet counts. Dose reduction, delay, or discontinuation may be required. Monitor for signs and symptoms of bleeding including petechiae, epistaxis, and gastrointestinal bleeding, especially if concomitant medication may increase the risk of bleeding.

    5.10 Increased HIV Viral Load

  In a randomized, placebo-controlled trial of thalidomide in an HIV-seropositive patient population, plasma HIV RNA levels were found to increase (median change = 0.42 log10copies HIV RNA/mL, p = 0.04 compared to placebo). A similar trend was observed in a second, unpublished study conducted in patients who were HIV-seropositive. The clinical significance of this increase is unknown. Both studies were conducted prior to availability of highly active antiretroviral therapy. Until the clinical significance of this finding is further understood, in HIV-seropositive patients, viral load should be measured after the first and third months of treatment and every 3 months thereafter.

    5.11 Bradycardia

  Bradycardia in association with thalidomide use has been reported. Cases of bradycardia have been reported, some required medical interventions. The clinical significance and underlying etiology of the bradycardia noted in some thalidomide-treated patients are presently unknown.  Monitor patients for bradycardia and syncope. Dose reduction or discontinuation may be required.

 Medications known to decrease heart rate should be used with caution in patients receiving thalidomide [see  Drug Interactions (7.2)  ]  .

    5.12 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  Serious dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, which may be fatal, have been reported. THALOMID should be discontinued if a skin rash occurs and only resumed following appropriate clinical evaluation. If the rash is exfoliative, purpuric, or bullous or if Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected, use of THALOMID should not be resumed.

    5.13 Seizures

  Although not reported from pre-marketing controlled clinical trials, seizures, including grand mal convulsions, have been reported during post-approval use of THALOMID in clinical practice. Because these events are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. Most patients had disorders that may have predisposed them to seizure activity, and it is not currently known whether thalidomide has any epileptogenic influence. During therapy with thalidomide, patients with a history of seizures or with other risk factors for the development of seizures should be monitored closely for clinical changes that could precipitate acute seizure activity.

    5.14 Tumor Lysis Syndrome

  Monitor patients at risk of tumor lysis syndrome (e.g., patients with high tumor burden prior to treatment) and take appropriate precautions.

    5.15 Contraceptive Risks

  Some contraceptive methods may pose a higher risk of adverse effects or may be medically contraindicated in some patients treated with THALOMID. Because some patients may develop sudden, severe neutropenia and/or thrombocytopenia, use of an intrauterine device (IUD) or implantable contraception in these patients may carry an increased risk for infection or bleeding either at insertion, removal or during use. Treatment with THALOMID, the presence of an underlying malignancy, and/or use of an estrogen-containing contraceptive can each increase the risk of thromboembolism. It is not known if these risks of thromboembolism are additive. However, they should be taken into consideration when choosing contraceptive methods.

    5.16 Hypersensitivity

  Hypersensitivity to THALOMID has been reported. Signs and symptoms have included the occurrence of erythematous macular rash, possibly associated with fever, tachycardia, and hypotension, and if severe, may necessitate interruption of therapy. If the reaction recurs when dosing is resumed, THALOMID should be discontinued.

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="19" name="heading" section="S1" start="2" />
    <IgnoredRegion len="26" name="heading" section="S3" start="3" />
    <IgnoredRegion len="2114" name="excerpt" section="S3" start="33" />
    <IgnoredRegion len="180" name="excerpt" section="S1" start="1779" />
    <IgnoredRegion len="1039" name="excerpt" section="S2" start="1888" />
    <IgnoredRegion len="30" name="heading" section="S1" start="1963" />
    <IgnoredRegion len="25" name="heading" section="S3" start="2154" />
    <IgnoredRegion len="25" name="heading" section="S3" start="5232" />
    <IgnoredRegion len="39" name="heading" section="S3" start="6378" />
    <IgnoredRegion len="118" name="heading" section="S3" start="7783" />
    <IgnoredRegion len="29" name="heading" section="S3" start="8331" />
    <IgnoredRegion len="25" name="heading" section="S3" start="8875" />
    <IgnoredRegion len="41" name="heading" section="S3" start="10854" />
    <IgnoredRegion len="15" name="heading" section="S3" start="11112" />
    <IgnoredRegion len="20" name="heading" section="S3" start="11773" />
    <IgnoredRegion len="29" name="heading" section="S3" start="12213" />
    <IgnoredRegion len="16" name="heading" section="S3" start="12936" />
    <IgnoredRegion len="60" name="heading" section="S3" start="13480" />
    <IgnoredRegion len="13" name="heading" section="S3" start="13964" />
    <IgnoredRegion len="25" name="heading" section="S3" start="14683" />
    <IgnoredRegion len="24" name="heading" section="S3" start="14859" />
    <IgnoredRegion len="21" name="heading" section="S3" start="15619" />
    <IgnoredRegion len="28" name="heading" section="S1" start="33115" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M99" len="14" reason="from_drug_use" section="S1" start="114" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M100" len="35" reason="from_drug_use" section="S1" start="245" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M101" len="24" reason="from_drug_use" section="S1" start="256" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arterial thromboembolism" meddra_llt_id="10073529" meddra_pt="Embolism arterial" meddra_pt_id="10014513" />
    </Mention>
    <Mention id="M14" len="9" reason="general_term" section="S1" start="399" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M102" len="10" reason="from_drug_use" section="S1" start="547" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drowsiness" meddra_llt_id="10013649" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M103" len="10" reason="from_drug_use" section="S1" start="562" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M104" len="21" reason="from_drug_use" section="S1" start="619" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy peripheral" meddra_llt_id="10029331" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M105" len="9" reason="from_drug_use" section="S1" start="687" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M106" len="23" reason="from_drug_use" section="S1" start="701" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Orthostatic hypotension" meddra_llt_id="10031127" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M107" len="11" reason="from_drug_use" section="S1" start="771" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M108" len="16" reason="from_drug_use" section="S1" start="829" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M109" len="24" reason="from_drug_use" section="S1" start="892" type="OSE_Labeled_AE">
      <Normalization meddra_llt="HIV viral load increased" meddra_llt_id="10049832" meddra_pt="Blood HIV RNA increased" meddra_pt_id="10049827" />
    </Mention>
    <Mention id="M110" len="11" reason="from_drug_use" section="S1" start="964" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M111" len="24" reason="from_drug_use" section="S1" start="1023" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syndrome Stevens-Johnson" meddra_llt_id="10042849" meddra_pt="Stevens-Johnson syndrome" meddra_pt_id="10042033" />
    </Mention>
    <Mention id="M112" len="26" reason="from_drug_use" section="S1" start="1052" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxic epidermal necrolysis" meddra_llt_id="10044223" meddra_pt="Toxic epidermal necrolysis" meddra_pt_id="10044223" />
    </Mention>
    <Mention id="M113" len="8" reason="from_drug_use" section="S1" start="1126" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M114" len="20" reason="from_drug_use" section="S1" start="1182" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tumor lysis syndrome" meddra_llt_id="10045152" meddra_pt="Tumour lysis syndrome" meddra_pt_id="10045170" />
    </Mention>
    <Mention id="M115" len="16" reason="from_drug_use" section="S1" start="1250" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M1" len="2" reason="indication" section="S1" start="1316" type="Not_AE_Candidate">
      <Normalization meddra_llt="Multiple myeloma" meddra_llt_id="10028228" meddra_pt="Plasma cell myeloma" meddra_pt_id="10035226" />
    </Mention>
    <Mention id="M116" len="7" reason="from_drug_use" section="S1" start="1367" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M117" len="12" reason="from_drug_use" section="S1" start="1376" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypocalcemia" meddra_llt_id="10020949" meddra_pt="Hypocalcaemia" meddra_pt_id="10020947" />
    </Mention>
    <Mention id="M118" len="5" reason="from_drug_use" section="S1" start="1390" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M119" len="12" reason="from_drug_use" section="S1" start="1397" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M120" len="18" reason="from_drug_use" section="S1" start="1411" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sensory neuropathy" meddra_llt_id="10062975" meddra_pt="Peripheral sensory neuropathy" meddra_pt_id="10034620" />
    </Mention>
    <Mention id="M121" len="7" reason="from_drug_use" section="S1" start="1431" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M122" len="15" reason="from_drug_use" section="S1" start="1440" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle weakness" meddra_llt_id="10028350" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M123" len="10" reason="from_drug_use" section="S1" start="1457" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M124" len="11" reason="from_drug_use" section="S1" start="1469" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M125" len="4" reason="from_drug_use" section="S1" start="1482" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M126" len="12" reason="from_drug_use" section="S1" start="1487" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Desquamation" meddra_llt_id="10012528" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" />
    </Mention>
    <Mention id="M127" len="9" reason="from_drug_use" section="S1" start="1501" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Confusion" meddra_llt_id="10010300" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Mention>
    <Mention id="M128" len="8" reason="from_drug_use" section="S1" start="1512" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M129" len="6" reason="from_drug_use" section="S1" start="1522" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M130" len="7" reason="from_drug_use" section="S1" start="1530" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M131" len="9" reason="from_drug_use" section="S1" start="1538" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M132" len="8" reason="from_drug_use" section="S1" start="1549" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M133" len="6" reason="from_drug_use" section="S1" start="1559" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M134" len="5" reason="from_drug_use" section="S1" start="1567" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fever" meddra_llt_id="10016558" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M135" len="11" reason="from_drug_use" section="S1" start="1574" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M136" len="10" reason="from_drug_use" section="S1" start="1587" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombosis" meddra_llt_id="10043607" meddra_pt="Thrombosis" meddra_pt_id="10043607" />
    </Mention>
    <Mention id="M137" len="8" reason="from_drug_use" section="S1" start="1598" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Embolism" meddra_llt_id="10061169" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M138" len="16" reason="from_drug_use" section="S1" start="1608" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral motor neuropathy" meddra_llt_id="10034580" meddra_pt="Peripheral motor neuropathy" meddra_pt_id="10034580" />
    </Mention>
    <Mention id="M139" len="11" reason="from_drug_use" section="S1" start="1626" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M140" len="9" reason="from_drug_use" section="S1" start="1639" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M141" len="8" reason="from_drug_use" section="S1" start="1654" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry skin" meddra_llt_id="10013786" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Mention>
    <Mention id="M2" len="3" reason="indication" section="S1" start="1679" type="Not_AE_Candidate">
      <Normalization meddra_llt="Erythema nodosum leprosum" meddra_llt_id="10067479" meddra_pt="Type 2 lepra reaction" meddra_pt_id="10070517" />
    </Mention>
    <Mention id="M142" len="10" reason="from_drug_use" section="S1" start="1731" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M143" len="4" reason="from_drug_use" section="S1" start="1743" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M144" len="8" reason="from_drug_use" section="S1" start="1753" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M574" len="20" reason="from_drug_use" section="S1" start="2441" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M575" len="13" reason="from_drug_use" section="S1" start="2482" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Birth defects" meddra_llt_id="10048305" meddra_pt="Congenital anomaly" meddra_pt_id="10010356" />
      <Normalization meddra_pt="Congenital anomaly in offspring" meddra_pt_id="10063726" />
    </Mention>
    <Mention id="M576" len="10" reason="from_drug_use" section="S1" start="2507" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Phocomelia" meddra_llt_id="10034923" meddra_pt="Limb reduction defect" meddra_pt_id="10024503" />
    </Mention>
    <Mention id="M577" len="18" reason="from_drug_use" section="S1" start="2521" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Death fetal" meddra_llt_id="10011908" meddra_pt="Foetal death" meddra_pt_id="10055690" />
    </Mention>
    <Mention id="M3" len="9" reason="preexisting_condition_or_risk_factor" section="S1" start="2589" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M15" len="13" reason="AE_only_as_instruction" section="S1" start="2772" type="NonOSE_AE">
      <Normalization meddra_llt="Birth defects" meddra_llt_id="10048305" meddra_pt="Congenital anomaly" meddra_pt_id="10010356" />
      <Normalization meddra_pt="Congenital anomaly in offspring" meddra_pt_id="10063726" />
    </Mention>
    <Mention id="M4" len="9" reason="contraindication" section="S1" start="2927" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M578" len="24" reason="from_drug_use" section="S1" start="3218" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arterial thromboembolism" meddra_llt_id="10073529" meddra_pt="Embolism arterial" meddra_pt_id="10014513" />
    </Mention>
    <Mention id="M145" len="22" reason="from_drug_use" section="S1" start="3269" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M146" len="20" reason="from_drug_use" section="S1" start="3301" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Deep vein thrombosis" meddra_llt_id="10051055" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M147" len="18" reason="from_drug_use" section="S1" start="3326" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary embolism" meddra_llt_id="10037377" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M148" len="22" reason="from_drug_use" section="S1" start="3347" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ischemic heart disease" meddra_llt_id="10055218" meddra_pt="Myocardial ischaemia" meddra_pt_id="10028600" />
    </Mention>
    <Mention id="M149" len="21" reason="from_drug_use" section="S1" start="3381" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M150" len="6" reason="from_drug_use" section="S1" start="3409" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M5" len="16" reason="indication" section="S1" start="3452" type="Not_AE_Candidate">
      <Normalization meddra_llt="Multiple myeloma" meddra_llt_id="10028228" meddra_pt="Plasma cell myeloma" meddra_pt_id="10035226" />
    </Mention>
    <Mention id="M151" len="21" reason="from_drug_use" section="S1" start="3569" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy peripheral" meddra_llt_id="10029331" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M152" len="21" reason="from_drug_use" section="S1" start="3717" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy peripheral" meddra_llt_id="10029331" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M579" len="10" reason="from_drug_use" section="S1" start="3881" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M153" len="10" reason="from_drug_use" section="S1" start="4129" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M154" len="9" reason="from_drug_use" section="S1" start="4141" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M155" len="4" reason="from_drug_use" section="S1" start="4156" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M156" len="7" reason="from_drug_use" section="S1" start="4707" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M157" len="12" reason="from_drug_use" section="S1" start="4716" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypocalcemia" meddra_llt_id="10020949" meddra_pt="Hypocalcaemia" meddra_pt_id="10020947" />
    </Mention>
    <Mention id="M158" len="5" reason="from_drug_use" section="S1" start="4730" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M159" len="12" reason="from_drug_use" section="S1" start="4737" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M160" len="18" reason="from_drug_use" section="S1" start="4751" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sensory neuropathy" meddra_llt_id="10062975" meddra_pt="Peripheral sensory neuropathy" meddra_pt_id="10034620" />
    </Mention>
    <Mention id="M161" len="7" reason="from_drug_use" section="S1" start="4771" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M162" len="15" reason="from_drug_use" section="S1" start="4780" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle weakness" meddra_llt_id="10028350" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M163" len="10" reason="from_drug_use" section="S1" start="4797" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M164" len="11" reason="from_drug_use" section="S1" start="4809" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M165" len="4" reason="from_drug_use" section="S1" start="4822" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M166" len="12" reason="from_drug_use" section="S1" start="4827" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Desquamation" meddra_llt_id="10012528" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" />
    </Mention>
    <Mention id="M167" len="9" reason="from_drug_use" section="S1" start="4841" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Confusion" meddra_llt_id="10010300" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Mention>
    <Mention id="M168" len="8" reason="from_drug_use" section="S1" start="4852" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M169" len="6" reason="from_drug_use" section="S1" start="4862" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M170" len="7" reason="from_drug_use" section="S1" start="4870" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M171" len="9" reason="from_drug_use" section="S1" start="4878" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M172" len="6" reason="from_drug_use" section="S1" start="4889" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M173" len="5" reason="from_drug_use" section="S1" start="4897" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fever" meddra_llt_id="10016558" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M174" len="11" reason="from_drug_use" section="S1" start="4904" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M175" len="10" reason="from_drug_use" section="S1" start="4917" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombosis" meddra_llt_id="10043607" meddra_pt="Thrombosis" meddra_pt_id="10043607" />
    </Mention>
    <Mention id="M176" len="8" reason="from_drug_use" section="S1" start="4928" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Embolism" meddra_llt_id="10061169" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M177" len="16" reason="from_drug_use" section="S1" start="4938" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral motor neuropathy" meddra_llt_id="10034580" meddra_pt="Peripheral motor neuropathy" meddra_pt_id="10034580" />
    </Mention>
    <Mention id="M178" len="11" reason="from_drug_use" section="S1" start="4956" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M179" len="9" reason="from_drug_use" section="S1" start="4969" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M180" len="8" reason="from_drug_use" section="S1" start="4984" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry skin" meddra_llt_id="10013786" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Mention>
    <Mention id="M16" len="20" reason="general_term" section="S1" start="5779" type="NonOSE_AE">
      <Normalization meddra_llt="Metabolic disorder" meddra_llt_id="10058097" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M181" len="12" reason="from_drug_use" section="S1" start="5921" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypocalcemia" meddra_llt_id="10020949" meddra_pt="Hypocalcaemia" meddra_pt_id="10020947" />
    </Mention>
    <Mention id="M17" len="9" reason="general_term" section="S1" start="6055" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder nervous system" meddra_llt_id="10013242" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M182" len="18" reason="from_drug_use" section="S1" start="6197" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sensory neuropathy" meddra_llt_id="10062975" meddra_pt="Peripheral sensory neuropathy" meddra_pt_id="10034620" />
    </Mention>
    <Mention id="M183" len="9" reason="from_drug_use" section="S1" start="6335" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Confusion" meddra_llt_id="10010300" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Mention>
    <Mention id="M581" len="7" reason="from_drug_use" section="S1" start="6473" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M580" len="9" reason="from_drug_use" section="S1" start="6481" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M184" len="6" reason="from_drug_use" section="S1" start="6611" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M185" len="16" reason="from_drug_use" section="S1" start="6749" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral motor neuropathy" meddra_llt_id="10034580" meddra_pt="Peripheral motor neuropathy" meddra_pt_id="10034580" />
    </Mention>
    <Mention id="M583" len="9" reason="from_drug_use" section="S1" start="6887" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M582" len="15" reason="from_drug_use" section="S1" start="6903" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lightheadedness" meddra_llt_id="10024492" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M186" len="37" reason="from_drug_use" section="S1" start="7037" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Depressed level of consciousness" meddra_llt_id="10012373" meddra_pt="Depressed level of consciousness" meddra_pt_id="10012373" />
    </Mention>
    <Mention id="M18" len="23" reason="general_term" section="S1" start="7189" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M187" len="7" reason="from_drug_use" section="S1" start="7333" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M188" len="5" reason="from_drug_use" section="S1" start="7471" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fever" meddra_llt_id="10016558" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M189" len="11" reason="from_drug_use" section="S1" start="7609" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M190" len="11" reason="from_drug_use" section="S1" start="7747" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M19" len="17" reason="general_term" section="S1" start="7881" type="NonOSE_AE">
      <Normalization meddra_llt="Blood disorder" meddra_llt_id="10061590" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M191" len="21" reason="from_drug_use" section="S1" start="8023" type="OSE_Labeled_AE">
      <Normalization meddra_llt="White blood cell count decreased" meddra_llt_id="10047942" meddra_pt="White blood cell count decreased" meddra_pt_id="10047942" />
    </Mention>
    <Mention id="M192" len="22" reason="from_drug_use" section="S1" start="8164" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutrophil count decreased" meddra_llt_id="10029366" meddra_pt="Neutrophil count decreased" meddra_pt_id="10029366" />
    </Mention>
    <Mention id="M25" len="16" reason="general_term" section="S1" start="8302" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M193" len="12" reason="from_drug_use" section="S1" start="8444" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M194" len="8" reason="from_drug_use" section="S1" start="8582" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M195" len="6" reason="from_drug_use" section="S1" start="8720" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M196" len="13" reason="from_drug_use" section="S1" start="8858" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oral dryness" meddra_llt_id="10030974" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M20" len="14" reason="general_term" section="S1" start="8992" type="NonOSE_AE">
      <Normalization meddra_llt="Instability cardiovascular" meddra_llt_id="10022453" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M197" len="5" reason="from_drug_use" section="S1" start="9134" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M584" len="10" reason="from_drug_use" section="S1" start="9272" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombosis" meddra_llt_id="10043607" meddra_pt="Thrombosis" meddra_pt_id="10043607" />
    </Mention>
    <Mention id="M585" len="8" reason="from_drug_use" section="S1" start="9283" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Embolism" meddra_llt_id="10061169" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M198" len="4" reason="from_drug_use" section="S1" start="9406" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain" meddra_llt_id="10033371" meddra_pt="Pain" meddra_pt_id="10033371" />
    </Mention>
    <Mention id="M199" len="7" reason="from_drug_use" section="S1" start="9548" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M200" len="10" reason="from_drug_use" section="S1" start="9686" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M21" len="9" reason="general_term" section="S1" start="9820" type="NonOSE_AE">
      <Normalization meddra_llt="Pulmonary disorder" meddra_llt_id="10037373" meddra_pt="Lung disorder" meddra_pt_id="10025082" />
    </Mention>
    <Mention id="M201" len="7" reason="from_drug_use" section="S1" start="9962" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M22" len="16" reason="general_term" section="S1" start="10096" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M202" len="4" reason="from_drug_use" section="S1" start="10238" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M203" len="12" reason="from_drug_use" section="S1" start="10243" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Desquamation" meddra_llt_id="10012528" meddra_pt="Skin exfoliation" meddra_pt_id="10040844" />
    </Mention>
    <Mention id="M204" len="8" reason="from_drug_use" section="S1" start="10376" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry skin" meddra_llt_id="10013786" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Mention>
    <Mention id="M23" len="7" reason="general_term" section="S1" start="10510" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder liver" meddra_llt_id="10013234" meddra_pt="Liver disorder" meddra_pt_id="10024670" />
      <Normalization meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
    </Mention>
    <Mention id="M586" len="9" reason="from_drug_use" section="S1" start="10652" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bilirubin" meddra_llt_id="10004683" meddra_pt="Blood bilirubin" meddra_pt_id="10005362" />
    </Mention>
    <Mention id="M24" len="15" reason="general_term" section="S1" start="10786" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal degeneration" meddra_llt_id="10074400" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M205" len="15" reason="from_drug_use" section="S1" start="10928" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle weakness" meddra_llt_id="10028350" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M206" len="12" reason="from_drug_use" section="S1" start="11434" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M207" len="16" reason="from_drug_use" section="S1" start="11448" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral edema" meddra_llt_id="10034570" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" />
    </Mention>
    <Mention id="M208" len="6" reason="from_drug_use" section="S1" start="11466" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M209" len="8" reason="from_drug_use" section="S1" start="11474" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M210" len="9" reason="from_drug_use" section="S1" start="11484" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M211" len="7" reason="from_drug_use" section="S1" start="11498" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M212" len="12" reason="from_drug_use" section="S1" start="11649" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M213" len="6" reason="from_drug_use" section="S1" start="11663" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M214" len="20" reason="from_drug_use" section="S1" start="11671" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Deep vein thrombosis" meddra_llt_id="10051055" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M215" len="29" reason="from_drug_use" section="S1" start="11696" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sensory peripheral neuropathy" meddra_llt_id="10040039" meddra_pt="Peripheral sensory neuropathy" meddra_pt_id="10034620" />
    </Mention>
    <Mention id="M26" len="52" reason="general_term" section="S1" start="12508" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M216" len="16" reason="from_drug_use" section="S1" start="12627" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral edema" meddra_llt_id="10034570" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" />
    </Mention>
    <Mention id="M217" len="8" reason="from_drug_use" section="S1" start="12711" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M218" len="7" reason="from_drug_use" section="S1" start="12795" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M587" len="5" reason="from_drug_use" section="S1" start="12879" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M27" len="26" reason="general_term" section="S1" start="12959" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M219" len="12" reason="from_drug_use" section="S1" start="13052" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M220" len="6" reason="from_drug_use" section="S1" start="13136" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M221" len="9" reason="from_drug_use" section="S1" start="13220" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M28" len="24" reason="general_term" section="S1" start="13300" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M222" len="6" reason="from_drug_use" section="S1" start="13391" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M223" len="9" reason="from_drug_use" section="S1" start="13475" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M224" len="11" reason="from_drug_use" section="S1" start="13559" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M225" len="29" reason="from_drug_use" section="S1" start="13643" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sensory peripheral neuropathy" meddra_llt_id="10040039" meddra_pt="Peripheral sensory neuropathy" meddra_pt_id="10034620" />
    </Mention>
    <Mention id="M29" len="27" reason="general_term" section="S1" start="13733" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M226" len="9" reason="from_drug_use" section="S1" start="13827" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pneumonia" meddra_llt_id="10035664" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M30" len="21" reason="general_term" section="S1" start="13907" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M227" len="7" reason="from_drug_use" section="S1" start="13995" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M228" len="10" reason="from_drug_use" section="S1" start="14079" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M31" len="34" reason="general_term" section="S1" start="14159" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified disorder of metabolism" meddra_llt_id="10045811" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M229" len="13" reason="from_drug_use" section="S1" start="14260" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M32" len="18" reason="general_term" section="S1" start="14340" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M230" len="20" reason="from_drug_use" section="S1" start="14428" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Deep vein thrombosis" meddra_llt_id="10051055" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M33" len="27" reason="general_term" section="S1" start="14986" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M588" len="9" reason="from_drug_use" section="S1" start="15080" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pneumonia" meddra_llt_id="10035664" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M589" len="16" reason="from_drug_use" section="S1" start="15164" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchopneumonia" meddra_llt_id="10006469" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M34" len="51" reason="general_term" section="S1" start="15245" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M231" len="8" reason="from_drug_use" section="S1" start="15363" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M35" len="33" reason="general_term" section="S1" start="15443" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified disorder of metabolism" meddra_llt_id="10045811" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M232" len="11" reason="from_drug_use" section="S1" start="15543" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypokalemia" meddra_llt_id="10021018" meddra_pt="Hypokalaemia" meddra_pt_id="10021015" />
      <Normalization meddra_pt="Blood potassium decreased" meddra_pt_id="10005724" />
    </Mention>
    <Mention id="M36" len="24" reason="general_term" section="S1" start="15623" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M233" len="7" reason="from_drug_use" section="S1" start="15714" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M590" len="21" reason="from_drug_use" section="S1" start="15798" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy peripheral" meddra_llt_id="10029331" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M234" len="24" reason="from_drug_use" section="S1" start="15888" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Accident cerebrovascular" meddra_llt_id="10000374" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M37" len="17" reason="general_term" section="S1" start="15973" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M235" len="19" reason="from_drug_use" section="S1" start="16061" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Atrial fibrillation" meddra_llt_id="10003658" meddra_pt="Atrial fibrillation" meddra_pt_id="10003658" />
    </Mention>
    <Mention id="M236" len="19" reason="from_drug_use" section="S1" start="16145" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial ischemia" meddra_llt_id="10028601" meddra_pt="Myocardial ischaemia" meddra_pt_id="10028600" />
    </Mention>
    <Mention id="M38" len="18" reason="general_term" section="S1" start="16225" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M237" len="20" reason="from_drug_use" section="S1" start="16313" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Deep vein thrombosis" meddra_llt_id="10051055" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M39" len="26" reason="general_term" section="S1" start="16394" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M238" len="12" reason="from_drug_use" section="S1" start="16487" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M40" len="14" reason="general_term" section="S1" start="16567" type="NonOSE_AE">
      <Normalization meddra_llt="Investigation" meddra_llt_id="10062026" meddra_pt="Investigation" meddra_pt_id="10062026" />
    </Mention>
    <Mention id="M239" len="16" reason="from_drug_use" section="S1" start="16655" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight increased" meddra_llt_id="10047899" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M41" len="35" reason="general_term" section="S1" start="16735" type="NonOSE_AE">
      <Normalization meddra_llt="Blood disorder" meddra_llt_id="10061590" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M591" len="11" reason="from_drug_use" section="S1" start="16837" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M42" len="47" reason="general_term" section="S1" start="16917" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M240" len="18" reason="from_drug_use" section="S1" start="17031" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary embolism" meddra_llt_id="10037377" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M43" len="21" reason="general_term" section="S1" start="17111" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M592" len="7" reason="from_drug_use" section="S1" start="17199" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M241" len="17" reason="from_drug_use" section="S1" start="17283" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Confusional state" meddra_llt_id="10010305" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Mention>
    <Mention id="M44" len="27" reason="general_term" section="S1" start="17363" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder ear" meddra_llt_id="10013214" meddra_pt="Ear disorder" meddra_pt_id="10014004" />
    </Mention>
    <Mention id="M242" len="7" reason="from_drug_use" section="S1" start="17457" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M6" len="16" reason="indication" section="S1" start="17702" type="Not_AE_Candidate">
      <Normalization meddra_llt="Multiple myeloma" meddra_llt_id="10028228" meddra_pt="Plasma cell myeloma" meddra_pt_id="10035226" />
    </Mention>
    <Mention id="M45" len="26" reason="general_term" section="S1" start="17797" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M243" len="8" reason="from_drug_use" section="S1" start="17826" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M244" len="9" reason="from_drug_use" section="S1" start="17840" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M245" len="11" reason="from_drug_use" section="S1" start="17851" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peritonitis" meddra_llt_id="10034674" meddra_pt="Peritonitis" meddra_pt_id="10034674" />
    </Mention>
    <Mention id="M246" len="24" reason="from_drug_use" section="S1" start="17864" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diverticular perforation" meddra_llt_id="10061820" meddra_pt="Diverticular perforation" meddra_pt_id="10061820" />
    </Mention>
    <Mention id="M46" len="24" reason="general_term" section="S1" start="17893" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M247" len="10" reason="from_drug_use" section="S1" start="17920" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M248" len="12" reason="from_drug_use" section="S1" start="17932" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypoesthesia" meddra_llt_id="10020976" meddra_pt="Hypoaesthesia" meddra_pt_id="10020937" />
    </Mention>
    <Mention id="M249" len="14" reason="from_drug_use" section="S1" start="17946" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Polyneuropathy" meddra_llt_id="10036105" meddra_pt="Polyneuropathy" meddra_pt_id="10036105" />
    </Mention>
    <Mention id="M250" len="25" reason="from_drug_use" section="S1" start="17966" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transient ischemic attack" meddra_llt_id="10072760" meddra_pt="Transient ischaemic attack" meddra_pt_id="10044390" />
    </Mention>
    <Mention id="M47" len="48" reason="general_term" section="S1" start="17996" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M251" len="10" reason="from_drug_use" section="S1" start="18047" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchitis" meddra_llt_id="10006451" meddra_pt="Bronchitis" meddra_pt_id="10006451" />
    </Mention>
    <Mention id="M48" len="21" reason="general_term" section="S1" start="18066" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M252" len="15" reason="from_drug_use" section="S1" start="18090" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mood alteration NOS" meddra_llt_id="10027937" meddra_pt="Mood altered" meddra_pt_id="10027940" />
    </Mention>
    <Mention id="M49" len="18" reason="general_term" section="S1" start="18114" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M253" len="11" reason="from_drug_use" section="S1" start="18135" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M254" len="23" reason="from_drug_use" section="S1" start="18152" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Orthostatic hypotension" meddra_llt_id="10031127" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M50" len="17" reason="general_term" section="S1" start="18180" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M255" len="11" reason="from_drug_use" section="S1" start="18200" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M51" len="13" reason="general_term" section="S1" start="18220" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M256" len="14" reason="from_drug_use" section="S1" start="18236" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision blurred" meddra_llt_id="10047513" meddra_pt="Vision blurred" meddra_pt_id="10047513" />
    </Mention>
    <Mention id="M7" len="3" reason="indication" section="S1" start="18996" type="Not_AE_Candidate">
      <Normalization meddra_llt="Erythema nodosum leprosum" meddra_llt_id="10067479" meddra_pt="Type 2 lepra reaction" meddra_pt_id="10070517" />
    </Mention>
    <Mention id="M257" len="10" reason="from_drug_use" section="S1" start="19078" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M258" len="4" reason="from_drug_use" section="S1" start="19090" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M259" len="8" reason="from_drug_use" section="S1" start="19096" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M52" len="19" reason="general_term" section="S1" start="19716" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified diseases of blood and blood-forming organs" meddra_llt_id="10045763" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M260" len="6" reason="from_drug_use" section="S1" start="19861" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anemia" meddra_llt_id="10002272" meddra_pt="Anaemia" meddra_pt_id="10002034" />
    </Mention>
    <Mention id="M261" len="10" reason="from_drug_use" section="S1" start="19999" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M262" len="15" reason="from_drug_use" section="S1" start="20137" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lymphadenopathy" meddra_llt_id="10025197" meddra_pt="Lymphadenopathy" meddra_pt_id="10025197" />
    </Mention>
    <Mention id="M53" len="15" reason="general_term" section="S1" start="20270" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M10" len="14" reason="AE_rate_lteq_placebo" section="S1" start="20413" type="NonOSE_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M263" len="17" reason="from_drug_use" section="S1" start="20551" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Non-accidental injury" meddra_llt_id="10029527" meddra_pt="Injury" meddra_pt_id="10022116" />
    </Mention>
    <Mention id="M264" len="8" reason="from_drug_use" section="S1" start="20689" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M265" len="9" reason="from_drug_use" section="S1" start="20827" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M11" len="6" reason="AE_rate_lteq_placebo" section="S1" start="20965" type="NonOSE_AE">
      <Normalization meddra_llt="Chills" meddra_llt_id="10008531" meddra_pt="Chills" meddra_pt_id="10008531" />
    </Mention>
    <Mention id="M593" len="12" reason="from_drug_use" section="S1" start="21103" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oedema face" meddra_llt_id="10030101" meddra_pt="Face oedema" meddra_pt_id="10016029" />
    </Mention>
    <Mention id="M266" len="5" reason="from_drug_use" section="S1" start="21241" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fever" meddra_llt_id="10016558" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M267" len="8" reason="from_drug_use" section="S1" start="21379" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M268" len="9" reason="from_drug_use" section="S1" start="21517" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M594" len="7" reason="from_drug_use" section="S1" start="21655" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Malaise" meddra_llt_id="10025482" meddra_pt="Malaise" meddra_pt_id="10025482" />
    </Mention>
    <Mention id="M595" len="9" reason="from_drug_use" section="S1" start="21793" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain neck" meddra_llt_id="10033467" meddra_pt="Neck pain" meddra_pt_id="10028836" />
    </Mention>
    <Mention id="M596" len="13" reason="from_drug_use" section="S1" start="21931" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neck rigidity" meddra_llt_id="10028839" meddra_pt="Nuchal rigidity" meddra_pt_id="10058483" />
    </Mention>
    <Mention id="M597" len="4" reason="from_drug_use" section="S1" start="22069" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain" meddra_llt_id="10033371" meddra_pt="Pain" meddra_pt_id="10033371" />
    </Mention>
    <Mention id="M54" len="16" reason="general_term" section="S1" start="22202" type="NonOSE_AE">
      <Normalization meddra_llt="Symptoms involving digestive system" meddra_llt_id="10042759" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M269" len="8" reason="from_drug_use" section="S1" start="22345" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M270" len="12" reason="from_drug_use" section="S1" start="22483" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M55" len="8" reason="AE_rate_lteq_placebo" section="S1" start="22621" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M271" len="9" reason="from_drug_use" section="S1" start="22759" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M272" len="10" reason="from_drug_use" section="S1" start="22897" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flatulence" meddra_llt_id="10016766" meddra_pt="Flatulence" meddra_pt_id="10016766" />
    </Mention>
    <Mention id="M598" len="54" reason="from_drug_use" section="S1" start="23035" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Liver function tests multiple abnorm" meddra_llt_id="10024694" meddra_pt="Liver function test abnormal" meddra_pt_id="10024690" />
    </Mention>
    <Mention id="M273" len="6" reason="from_drug_use" section="S1" start="23209" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M274" len="15" reason="from_drug_use" section="S1" start="23347" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Moniliasis oral" meddra_llt_id="10027835" meddra_pt="Oral candidiasis" meddra_pt_id="10030963" />
    </Mention>
    <Mention id="M599" len="10" reason="from_drug_use" section="S1" start="23485" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tooth pain" meddra_llt_id="10059723" meddra_pt="Toothache" meddra_pt_id="10044055" />
    </Mention>
    <Mention id="M56" len="33" reason="general_term" section="S1" start="23618" type="NonOSE_AE">
      <Normalization meddra_llt="Metabolic disorder" meddra_llt_id="10058097" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M275" len="16" reason="from_drug_use" section="S1" start="23773" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral edema" meddra_llt_id="10034570" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" />
    </Mention>
    <Mention id="M276" len="12" reason="from_drug_use" section="S1" start="23911" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperlipemia" meddra_llt_id="10020662" meddra_pt="Hyperlipidaemia" meddra_pt_id="10062060" />
    </Mention>
    <Mention id="M277" len="14" reason="from_drug_use" section="S1" start="24049" type="OSE_Labeled_AE">
      <Normalization meddra_llt="SGOT increased" meddra_llt_id="10040524" meddra_pt="Aspartate aminotransferase increased" meddra_pt_id="10003481" />
    </Mention>
    <Mention id="M57" len="14" reason="general_term" section="S1" start="24182" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder nervous system" meddra_llt_id="10013242" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M278" len="9" reason="from_drug_use" section="S1" start="24325" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M279" len="9" reason="from_drug_use" section="S1" start="24463" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M280" len="8" reason="from_drug_use" section="S1" start="24601" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M281" len="11" reason="from_drug_use" section="S1" start="24739" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nervousness" meddra_llt_id="10029216" meddra_pt="Nervousness" meddra_pt_id="10029216" />
    </Mention>
    <Mention id="M282" len="10" reason="from_drug_use" section="S1" start="24877" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M283" len="11" reason="from_drug_use" section="S1" start="25015" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M284" len="10" reason="from_drug_use" section="S1" start="25153" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M600" len="6" reason="from_drug_use" section="S1" start="25291" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M601" len="7" reason="from_drug_use" section="S1" start="25429" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M58" len="18" reason="general_term" section="S1" start="25562" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder respiratory system" meddra_llt_id="10013264" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M285" len="11" reason="from_drug_use" section="S1" start="25705" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngitis" meddra_llt_id="10034835" meddra_pt="Pharyngitis" meddra_pt_id="10034835" />
    </Mention>
    <Mention id="M12" len="8" reason="AE_rate_lteq_placebo" section="S1" start="25843" type="NonOSE_AE">
      <Normalization meddra_llt="Rhinitis" meddra_llt_id="10039083" meddra_pt="Rhinitis" meddra_pt_id="10039083" />
    </Mention>
    <Mention id="M286" len="9" reason="from_drug_use" section="S1" start="25981" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sinusitis" meddra_llt_id="10040753" meddra_pt="Sinusitis" meddra_pt_id="10040753" />
    </Mention>
    <Mention id="M59" len="19" reason="general_term" section="S1" start="26114" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M287" len="4" reason="from_drug_use" section="S1" start="26257" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Acne" meddra_llt_id="10000496" meddra_pt="Acne" meddra_pt_id="10000496" />
    </Mention>
    <Mention id="M288" len="17" reason="from_drug_use" section="S1" start="26395" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fungal dermatitis" meddra_llt_id="10017526" meddra_pt="Fungal skin infection" meddra_pt_id="10017543" />
    </Mention>
    <Mention id="M289" len="13" reason="from_drug_use" section="S1" start="26533" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nail disorder" meddra_llt_id="10028694" meddra_pt="Nail disorder" meddra_pt_id="10028694" />
    </Mention>
    <Mention id="M60" len="8" reason="AE_rate_lteq_placebo" section="S1" start="26671" type="NonOSE_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M13" len="4" reason="AE_rate_lteq_placebo" section="S1" start="26809" type="NonOSE_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M290" len="18" reason="from_drug_use" section="S1" start="26947" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Maculopapular rash" meddra_llt_id="10025424" meddra_pt="Rash maculo-papular" meddra_pt_id="10037868" />
    </Mention>
    <Mention id="M61" len="8" reason="AE_rate_lteq_placebo" section="S1" start="27085" type="NonOSE_AE">
      <Normalization meddra_llt="Sweating" meddra_llt_id="10042661" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Mention>
    <Mention id="M62" len="17" reason="general_term" section="S1" start="27218" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder urogenital" meddra_llt_id="10013279" meddra_pt="Urogenital disorder" meddra_pt_id="10046694" />
    </Mention>
    <Mention id="M291" len="11" reason="from_drug_use" section="S1" start="27361" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Albuminuria" meddra_llt_id="10001580" meddra_pt="Albuminuria" meddra_pt_id="10001580" />
    </Mention>
    <Mention id="M292" len="9" reason="from_drug_use" section="S1" start="27499" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hematuria" meddra_llt_id="10019450" meddra_pt="Haematuria" meddra_pt_id="10018867" />
    </Mention>
    <Mention id="M293" len="9" reason="from_drug_use" section="S1" start="27637" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Impotence" meddra_llt_id="10021550" meddra_pt="Erectile dysfunction" meddra_pt_id="10061461" />
    </Mention>
    <Mention id="M8" len="3" reason="indication" section="S1" start="27967" type="Not_AE_Candidate">
      <Normalization meddra_llt="Erythema nodosum leprosum" meddra_llt_id="10067479" meddra_pt="Type 2 lepra reaction" meddra_pt_id="10070517" />
    </Mention>
    <Mention id="M63" len="19" reason="general_term" section="S1" start="28752" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified diseases of blood and blood-forming organs" meddra_llt_id="10045763" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M294" len="12" reason="from_drug_use" section="S1" start="28774" type="OSE_Labeled_AE">
      <Normalization meddra_llt="ESR low" meddra_llt_id="10015481" meddra_pt="Red blood cell sedimentation rate decreased" meddra_pt_id="10049188" />
    </Mention>
    <Mention id="M295" len="12" reason="from_drug_use" section="S1" start="28788" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eosinophilia" meddra_llt_id="10014950" meddra_pt="Eosinophilia" meddra_pt_id="10014950" />
    </Mention>
    <Mention id="M296" len="16" reason="from_drug_use" section="S1" start="28802" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Granulocytopenia" meddra_llt_id="10018687" meddra_pt="Granulocytopenia" meddra_pt_id="10018687" />
    </Mention>
    <Mention id="M297" len="18" reason="from_drug_use" section="S1" start="28820" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypochromic anemia" meddra_llt_id="10020971" meddra_pt="Hypochromic anaemia" meddra_pt_id="10020969" />
    </Mention>
    <Mention id="M298" len="8" reason="from_drug_use" section="S1" start="28840" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukemia" meddra_llt_id="10024329" meddra_pt="Leukaemia" meddra_pt_id="10024288" />
    </Mention>
    <Mention id="M299" len="12" reason="from_drug_use" section="S1" start="28850" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukocytosis" meddra_llt_id="10024378" meddra_pt="Leukocytosis" meddra_pt_id="10024378" />
    </Mention>
    <Mention id="M300" len="10" reason="from_drug_use" section="S1" start="28864" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M301" len="12" reason="from_drug_use" section="S1" start="28876" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mean cell volume increased" meddra_llt_id="10027004" meddra_pt="Mean cell volume increased" meddra_pt_id="10027004" />
    </Mention>
    <Mention id="M302" len="12" reason="from_drug_use" section="S1" start="28890" type="OSE_Labeled_AE">
      <Normalization meddra_llt="RBC count abnormal" meddra_llt_id="10037923" meddra_pt="Red blood cell count abnormal" meddra_pt_id="10038151" />
    </Mention>
    <Mention id="M303" len="15" reason="from_drug_use" section="S1" start="28904" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Spleen palpable" meddra_llt_id="10057471" meddra_pt="Spleen palpable" meddra_pt_id="10057471" />
    </Mention>
    <Mention id="M304" len="16" reason="from_drug_use" section="S1" start="28921" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M64" len="15" reason="general_term" section="S1" start="28943" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M305" len="16" reason="from_drug_use" section="S1" start="28961" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abdomen enlarged" meddra_llt_id="10000045" meddra_pt="Abdominal distension" meddra_pt_id="10000060" />
    </Mention>
    <Mention id="M306" len="5" reason="from_drug_use" section="S1" start="28979" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fever" meddra_llt_id="10016558" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M307" len="16" reason="from_drug_use" section="S1" start="28986" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Photosensitivity" meddra_llt_id="10034966" meddra_pt="Photosensitivity reaction" meddra_pt_id="10034972" />
    </Mention>
    <Mention id="M308" len="20" reason="from_drug_use" section="S1" start="29004" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain in extremity" meddra_llt_id="10033425" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M65" len="21" reason="general_term" section="S1" start="29030" type="NonOSE_AE">
      <Normalization meddra_llt="Symptoms involving cardiovascular system" meddra_llt_id="10042758" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M309" len="11" reason="from_drug_use" section="S1" start="29054" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M310" len="12" reason="from_drug_use" section="S1" start="29067" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M311" len="11" reason="from_drug_use" section="S1" start="29081" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M312" len="28" reason="from_drug_use" section="S1" start="29094" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder peripheral vascular" meddra_llt_id="10013255" meddra_pt="Peripheral vascular disorder" meddra_pt_id="10034636" />
    </Mention>
    <Mention id="M313" len="11" reason="from_drug_use" section="S1" start="29124" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M314" len="12" reason="from_drug_use" section="S1" start="29137" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vasodilatation" meddra_llt_id="10047141" meddra_pt="Vasodilatation" meddra_pt_id="10047141" />
    </Mention>
    <Mention id="M66" len="16" reason="general_term" section="S1" start="29155" type="NonOSE_AE">
      <Normalization meddra_llt="Symptoms involving digestive system" meddra_llt_id="10042759" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M315" len="8" reason="from_drug_use" section="S1" start="29174" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M316" len="17" reason="from_drug_use" section="S1" start="29184" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased appetite" meddra_llt_id="10021654" meddra_pt="Increased appetite" meddra_pt_id="10021654" />
    </Mention>
    <Mention id="M317" len="11" reason="from_drug_use" section="S1" start="29202" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M318" len="9" reason="from_drug_use" section="S1" start="29215" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M319" len="9" reason="from_drug_use" section="S1" start="29226" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M320" len="14" reason="from_drug_use" section="S1" start="29237" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatomegaly" meddra_llt_id="10019842" meddra_pt="Hepatomegaly" meddra_pt_id="10019842" />
    </Mention>
    <Mention id="M321" len="10" reason="from_drug_use" section="S1" start="29253" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eructation" meddra_llt_id="10015137" meddra_pt="Eructation" meddra_pt_id="10015137" />
    </Mention>
    <Mention id="M322" len="10" reason="from_drug_use" section="S1" start="29265" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flatulence" meddra_llt_id="10016766" meddra_pt="Flatulence" meddra_pt_id="10016766" />
    </Mention>
    <Mention id="M323" len="30" reason="from_drug_use" section="S1" start="29277" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Liver function test increased" meddra_llt_id="10077692" meddra_pt="Liver function test increased" meddra_pt_id="10077692" />
    </Mention>
    <Mention id="M324" len="22" reason="from_drug_use" section="S1" start="29309" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Obstruction intestinal" meddra_llt_id="10029958" meddra_pt="Intestinal obstruction" meddra_pt_id="10022687" />
    </Mention>
    <Mention id="M325" len="8" reason="from_drug_use" section="S1" start="29333" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M67" len="23" reason="general_term" section="S1" start="29347" type="NonOSE_AE">
      <Normalization meddra_llt="Other transitory neonatal endocrine and metabolic disturbances" meddra_llt_id="10033002" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M326" len="17" reason="from_drug_use" section="S1" start="29373" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Inappropriate ADH" meddra_llt_id="10021586" meddra_pt="Inappropriate antidiuretic hormone secretion" meddra_pt_id="10053198" />
    </Mention>
    <Mention id="M327" len="11" reason="from_drug_use" section="S1" start="29392" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amyloidosis" meddra_llt_id="10002022" meddra_pt="Amyloidosis" meddra_pt_id="10002022" />
    </Mention>
    <Mention id="M328" len="13" reason="from_drug_use" section="S1" start="29405" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bilirubinemia" meddra_llt_id="10004705" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M329" len="13" reason="from_drug_use" section="S1" start="29420" type="OSE_Labeled_AE">
      <Normalization meddra_llt="BUN increased" meddra_llt_id="10006576" meddra_pt="Blood urea increased" meddra_pt_id="10005851" />
    </Mention>
    <Mention id="M330" len="20" reason="from_drug_use" section="S1" start="29435" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Creatinine increased" meddra_llt_id="10011368" meddra_pt="Blood creatinine increased" meddra_pt_id="10005483" />
    </Mention>
    <Mention id="M331" len="8" reason="from_drug_use" section="S1" start="29457" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cyanosis" meddra_llt_id="10011703" meddra_pt="Cyanosis" meddra_pt_id="10011703" />
    </Mention>
    <Mention id="M332" len="8" reason="from_drug_use" section="S1" start="29467" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diabetes" meddra_llt_id="10012594" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Mention>
    <Mention id="M333" len="5" reason="from_drug_use" section="S1" start="29477" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M334" len="25" reason="from_drug_use" section="S1" start="29484" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Electrolyte abnormality" meddra_llt_id="10014410" meddra_pt="Electrolyte imbalance" meddra_pt_id="10014418" />
      <Normalization meddra_pt="Blood electrolytes abnormal" meddra_pt_id="10061014" />
    </Mention>
    <Mention id="M335" len="13" reason="from_drug_use" section="S1" start="29511" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M336" len="12" reason="from_drug_use" section="S1" start="29526" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperkalemia" meddra_llt_id="10020647" meddra_pt="Hyperkalaemia" meddra_pt_id="10020646" />
    </Mention>
    <Mention id="M337" len="13" reason="from_drug_use" section="S1" start="29540" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperuricemia" meddra_llt_id="10020907" meddra_pt="Hyperuricaemia" meddra_pt_id="10020903" />
    </Mention>
    <Mention id="M338" len="12" reason="from_drug_use" section="S1" start="29555" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypocalcemia" meddra_llt_id="10020949" meddra_pt="Hypocalcaemia" meddra_pt_id="10020947" />
    </Mention>
    <Mention id="M339" len="15" reason="from_drug_use" section="S1" start="29569" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypoproteinemia" meddra_llt_id="10021084" meddra_pt="Hypoproteinaemia" meddra_pt_id="10021083" />
    </Mention>
    <Mention id="M340" len="13" reason="from_drug_use" section="S1" start="29586" type="OSE_Labeled_AE">
      <Normalization meddra_llt="LDH increased" meddra_llt_id="10024051" meddra_pt="Blood lactate dehydrogenase increased" meddra_pt_id="10005630" />
    </Mention>
    <Mention id="M341" len="20" reason="from_drug_use" section="S1" start="29601" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood phosphorus decreased" meddra_llt_id="10049471" meddra_pt="Blood phosphorus decreased" meddra_pt_id="10049471" />
    </Mention>
    <Mention id="M342" len="14" reason="from_drug_use" section="S1" start="29623" type="OSE_Labeled_AE">
      <Normalization meddra_llt="SGPT increased" meddra_llt_id="10040526" meddra_pt="Alanine aminotransferase increased" meddra_pt_id="10001551" />
    </Mention>
    <Mention id="M68" len="17" reason="general_term" section="S1" start="29643" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal degeneration" meddra_llt_id="10074400" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M343" len="9" reason="from_drug_use" section="S1" start="29663" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthritis" meddra_llt_id="10003246" meddra_pt="Arthritis" meddra_pt_id="10003246" />
    </Mention>
    <Mention id="M602" len="15" reason="from_drug_use" section="S1" start="29674" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bone tenderness" meddra_llt_id="10065017" meddra_pt="Bone pain" meddra_pt_id="10006002" />
    </Mention>
    <Mention id="M344" len="10" reason="from_drug_use" section="S1" start="29691" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertonia" meddra_llt_id="10020852" meddra_pt="Hypertonia" meddra_pt_id="10020852" />
    </Mention>
    <Mention id="M345" len="14" reason="from_drug_use" section="S1" start="29703" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder joint" meddra_llt_id="10013230" meddra_pt="Arthropathy" meddra_pt_id="10003285" />
    </Mention>
    <Mention id="M346" len="10" reason="from_drug_use" section="S1" start="29719" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cramps leg" meddra_llt_id="10011297" meddra_pt="Muscle spasms" meddra_pt_id="10028334" />
    </Mention>
    <Mention id="M347" len="7" reason="from_drug_use" section="S1" start="29731" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M348" len="10" reason="from_drug_use" section="S1" start="29740" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myasthenia" meddra_llt_id="10028415" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M349" len="19" reason="from_drug_use" section="S1" start="29752" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder periosteal" meddra_llt_id="10013254" meddra_pt="Bone disorder" meddra_pt_id="10005956" />
    </Mention>
    <Mention id="M69" len="14" reason="general_term" section="S1" start="29777" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder nervous system" meddra_llt_id="10013242" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M350" len="17" reason="from_drug_use" section="S1" start="29794" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thinking abnormal" meddra_llt_id="10043431" meddra_pt="Thinking abnormal" meddra_pt_id="10043431" />
    </Mention>
    <Mention id="M351" len="9" reason="from_drug_use" section="S1" start="29813" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M352" len="7" reason="from_drug_use" section="S1" start="29824" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amnesia" meddra_llt_id="10001949" meddra_pt="Amnesia" meddra_pt_id="10001949" />
    </Mention>
    <Mention id="M353" len="7" reason="from_drug_use" section="S1" start="29833" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M354" len="9" reason="from_drug_use" section="S1" start="29842" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Causalgia" meddra_llt_id="10007825" meddra_pt="Complex regional pain syndrome" meddra_pt_id="10064332" />
    </Mention>
    <Mention id="M355" len="22" reason="from_drug_use" section="S1" start="29853" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Circumoral paresthesia" meddra_llt_id="10009201" meddra_pt="Paraesthesia oral" meddra_pt_id="10057372" />
    </Mention>
    <Mention id="M356" len="9" reason="from_drug_use" section="S1" start="29877" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Confusion" meddra_llt_id="10010300" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Mention>
    <Mention id="M357" len="10" reason="from_drug_use" section="S1" start="29888" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M603" len="8" reason="from_drug_use" section="S1" start="29900" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Euphoria" meddra_llt_id="10015533" meddra_pt="Euphoric mood" meddra_pt_id="10015535" />
    </Mention>
    <Mention id="M358" len="13" reason="from_drug_use" section="S1" start="29910" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperesthesia" meddra_llt_id="10020622" meddra_pt="Hyperaesthesia" meddra_pt_id="10020568" />
    </Mention>
    <Mention id="M359" len="8" reason="from_drug_use" section="S1" start="29925" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M360" len="11" reason="from_drug_use" section="S1" start="29935" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nervousness" meddra_llt_id="10029216" meddra_pt="Nervousness" meddra_pt_id="10029216" />
    </Mention>
    <Mention id="M361" len="9" reason="from_drug_use" section="S1" start="29948" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuralgia" meddra_llt_id="10029223" meddra_pt="Neuralgia" meddra_pt_id="10029223" />
    </Mention>
    <Mention id="M362" len="8" reason="from_drug_use" section="S1" start="29959" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuritis" meddra_llt_id="10029240" meddra_pt="Neuritis" meddra_pt_id="10029240" />
    </Mention>
    <Mention id="M363" len="10" reason="from_drug_use" section="S1" start="29969" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M364" len="11" reason="from_drug_use" section="S1" start="29981" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M365" len="19" reason="from_drug_use" section="S1" start="29994" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuritis peripheral" meddra_llt_id="10029248" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M366" len="9" reason="from_drug_use" section="S1" start="30015" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychosis" meddra_llt_id="10037234" meddra_pt="Psychotic disorder" meddra_pt_id="10061920" />
    </Mention>
    <Mention id="M70" len="18" reason="general_term" section="S1" start="30030" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder respiratory system" meddra_llt_id="10013264" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M367" len="5" reason="from_drug_use" section="S1" start="30051" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cough" meddra_llt_id="10011224" meddra_pt="Cough" meddra_pt_id="10011224" />
    </Mention>
    <Mention id="M368" len="9" reason="from_drug_use" section="S1" start="30058" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Emphysema" meddra_llt_id="10014561" meddra_pt="Emphysema" meddra_pt_id="10014561" />
    </Mention>
    <Mention id="M369" len="9" reason="from_drug_use" section="S1" start="30069" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Epistaxis" meddra_llt_id="10015090" meddra_pt="Epistaxis" meddra_pt_id="10015090" />
    </Mention>
    <Mention id="M370" len="17" reason="from_drug_use" section="S1" start="30080" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary embolus" meddra_llt_id="10037380" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M371" len="5" reason="from_drug_use" section="S1" start="30099" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rales" meddra_llt_id="10037833" meddra_pt="Rales" meddra_pt_id="10037833" />
    </Mention>
    <Mention id="M372" len="27" reason="from_drug_use" section="S1" start="30106" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory infection" meddra_llt_id="10046300" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M373" len="16" reason="from_drug_use" section="S1" start="30135" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Voice alteration" meddra_llt_id="10047681" meddra_pt="Dysphonia" meddra_pt_id="10013952" />
    </Mention>
    <Mention id="M71" len="19" reason="general_term" section="S1" start="30157" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M374" len="4" reason="from_drug_use" section="S1" start="30179" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Acne" meddra_llt_id="10000496" meddra_pt="Acne" meddra_pt_id="10000496" />
    </Mention>
    <Mention id="M375" len="8" reason="from_drug_use" section="S1" start="30185" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alopecia" meddra_llt_id="10001760" meddra_pt="Alopecia" meddra_pt_id="10001760" />
    </Mention>
    <Mention id="M376" len="8" reason="from_drug_use" section="S1" start="30195" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry skin" meddra_llt_id="10013786" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Mention>
    <Mention id="M377" len="15" reason="from_drug_use" section="S1" start="30205" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eczematous rash" meddra_llt_id="10014209" meddra_pt="Eczema" meddra_pt_id="10014184" />
    </Mention>
    <Mention id="M378" len="22" reason="from_drug_use" section="S1" start="30222" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dermatitis exfoliative" meddra_llt_id="10012455" meddra_pt="Dermatitis exfoliative" meddra_pt_id="10012455" />
    </Mention>
    <Mention id="M379" len="10" reason="from_drug_use" section="S1" start="30246" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ichthyosis" meddra_llt_id="10021198" meddra_pt="Ichthyosis" meddra_pt_id="10021198" />
    </Mention>
    <Mention id="M380" len="25" reason="from_drug_use" section="S1" start="30258" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin thickening" meddra_llt_id="10040936" meddra_pt="Skin hypertrophy" meddra_pt_id="10040867" />
    </Mention>
    <Mention id="M381" len="13" reason="from_drug_use" section="S1" start="30285" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin necrosis" meddra_llt_id="10040893" meddra_pt="Skin necrosis" meddra_pt_id="10040893" />
    </Mention>
    <Mention id="M382" len="9" reason="from_drug_use" section="S1" start="30300" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seborrhea" meddra_llt_id="10039786" meddra_pt="Seborrhoea" meddra_pt_id="10039792" />
    </Mention>
    <Mention id="M383" len="8" reason="from_drug_use" section="S1" start="30311" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sweating" meddra_llt_id="10042661" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Mention>
    <Mention id="M384" len="9" reason="from_drug_use" section="S1" start="30321" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urticaria" meddra_llt_id="10046735" meddra_pt="Urticaria" meddra_pt_id="10046735" />
    </Mention>
    <Mention id="M385" len="20" reason="from_drug_use" section="S1" start="30332" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash vesiculobullous" meddra_llt_id="10037901" meddra_pt="Dermatitis bullous" meddra_pt_id="10012441" />
    </Mention>
    <Mention id="M72" len="14" reason="general_term" section="S1" start="30358" type="NonOSE_AE">
      <Normalization meddra_llt="Cranial nerve disorder" meddra_llt_id="10061093" meddra_pt="Cranial nerve disorder" meddra_pt_id="10061093" />
    </Mention>
    <Mention id="M386" len="9" reason="from_drug_use" section="S1" start="30375" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amblyopia" meddra_llt_id="10001906" meddra_pt="Amblyopia" meddra_pt_id="10001906" />
    </Mention>
    <Mention id="M387" len="8" reason="from_drug_use" section="S1" start="30386" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Deafness" meddra_llt_id="10011878" meddra_pt="Deafness" meddra_pt_id="10011878" />
    </Mention>
    <Mention id="M388" len="7" reason="from_drug_use" section="S1" start="30396" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry eye" meddra_llt_id="10013774" meddra_pt="Dry eye" meddra_pt_id="10013774" />
    </Mention>
    <Mention id="M389" len="8" reason="from_drug_use" section="S1" start="30405" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain eye" meddra_llt_id="10033397" meddra_pt="Eye pain" meddra_pt_id="10015958" />
    </Mention>
    <Mention id="M390" len="8" reason="from_drug_use" section="S1" start="30415" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tinnitus" meddra_llt_id="10043882" meddra_pt="Tinnitus" meddra_pt_id="10043882" />
    </Mention>
    <Mention id="M73" len="10" reason="general_term" section="S1" start="30429" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder urogenital" meddra_llt_id="10013279" meddra_pt="Urogenital disorder" meddra_pt_id="10046694" />
    </Mention>
    <Mention id="M391" len="30" reason="from_drug_use" section="S1" start="30442" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Creatinine clearance decreased" meddra_llt_id="10011363" meddra_pt="Creatinine renal clearance decreased" meddra_pt_id="10011372" />
    </Mention>
    <Mention id="M392" len="9" reason="from_drug_use" section="S1" start="30474" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hematuria" meddra_llt_id="10019450" meddra_pt="Haematuria" meddra_pt_id="10018867" />
    </Mention>
    <Mention id="M393" len="8" reason="from_drug_use" section="S1" start="30485" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Epididymo-orchitis" meddra_llt_id="10015005" meddra_pt="Orchitis" meddra_pt_id="10031064" />
    </Mention>
    <Mention id="M394" len="11" reason="from_drug_use" section="S1" start="30495" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Proteinuria-aggravated" meddra_llt_id="10048484" meddra_pt="Proteinuria" meddra_pt_id="10037032" />
    </Mention>
    <Mention id="M395" len="6" reason="from_drug_use" section="S1" start="30508" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pyuria" meddra_llt_id="10037686" meddra_pt="Pyuria" meddra_pt_id="10037686" />
    </Mention>
    <Mention id="M396" len="17" reason="from_drug_use" section="S1" start="30516" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Frequency urinary" meddra_llt_id="10017366" meddra_pt="Pollakiuria" meddra_pt_id="10036018" />
    </Mention>
    <Mention id="M9" len="16" reason="preexisting_condition_or_risk_factor" section="S1" start="30771" type="Not_AE_Candidate">
      <Normalization meddra_llt="HIV seropositive NOS" meddra_llt_id="10020183" meddra_pt="HIV test positive" meddra_pt_id="10020188" />
    </Mention>
    <Mention id="M74" len="19" reason="general_term" section="S1" start="31123" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified diseases of blood and blood-forming organs" meddra_llt_id="10045763" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M397" len="15" reason="from_drug_use" section="S1" start="31145" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Aplastic anemia" meddra_llt_id="10002969" meddra_pt="Aplastic anaemia" meddra_pt_id="10002967" />
    </Mention>
    <Mention id="M398" len="17" reason="from_drug_use" section="S1" start="31162" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anemia macrocytic" meddra_llt_id="10002297" meddra_pt="Anaemia macrocytic" meddra_pt_id="10002064" />
    </Mention>
    <Mention id="M399" len="20" reason="from_drug_use" section="S1" start="31181" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Megaloblastic anemia" meddra_llt_id="10027129" meddra_pt="Anaemia megaloblastic" meddra_pt_id="10002065" />
    </Mention>
    <Mention id="M400" len="17" reason="from_drug_use" section="S1" start="31203" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Microcytic anemia" meddra_llt_id="10027539" meddra_pt="Microcytic anaemia" meddra_pt_id="10027538" />
    </Mention>
    <Mention id="M75" len="15" reason="general_term" section="S1" start="31226" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M401" len="7" reason="from_drug_use" section="S1" start="31244" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ascites" meddra_llt_id="10003445" meddra_pt="Ascites" meddra_pt_id="10003445" />
    </Mention>
    <Mention id="M402" len="4" reason="from_drug_use" section="S1" start="31253" type="OSE_Labeled_AE">
      <Normalization meddra_llt="AIDS" meddra_llt_id="10001509" meddra_pt="Acquired immunodeficiency syndrome" meddra_pt_id="10000565" />
    </Mention>
    <Mention id="M403" len="17" reason="from_drug_use" section="S1" start="31259" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Allergic reaction" meddra_llt_id="10001718" meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
      <Normalization meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
    </Mention>
    <Mention id="M404" len="10" reason="from_drug_use" section="S1" start="31278" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cellulitis" meddra_llt_id="10007882" meddra_pt="Cellulitis" meddra_pt_id="10007882" />
    </Mention>
    <Mention id="M405" len="10" reason="from_drug_use" section="S1" start="31290" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M406" len="6" reason="from_drug_use" section="S1" start="31302" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Chills" meddra_llt_id="10008531" meddra_pt="Chills" meddra_pt_id="10008531" />
    </Mention>
    <Mention id="M407" len="5" reason="from_drug_use" section="S1" start="31313" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fever" meddra_llt_id="10016558" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M408" len="4" reason="from_drug_use" section="S1" start="31320" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cyst" meddra_llt_id="10011732" meddra_pt="Cyst" meddra_pt_id="10011732" />
    </Mention>
    <Mention id="M409" len="19" reason="from_drug_use" section="S1" start="31326" type="OSE_Labeled_AE">
      <Normalization meddra_llt="CD4 lymphocytes decreased" meddra_llt_id="10007839" meddra_pt="CD4 lymphocytes decreased" meddra_pt_id="10007839" />
    </Mention>
    <Mention id="M410" len="12" reason="from_drug_use" section="S1" start="31347" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oedema face" meddra_llt_id="10030101" meddra_pt="Face oedema" meddra_pt_id="10016029" />
    </Mention>
    <Mention id="M411" len="12" reason="from_drug_use" section="S1" start="31361" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flu syndrome" meddra_llt_id="10016793" meddra_pt="Influenza" meddra_pt_id="10022000" />
    </Mention>
    <Mention id="M412" len="6" reason="from_drug_use" section="S1" start="31375" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hernia" meddra_llt_id="10019909" meddra_pt="Hernia" meddra_pt_id="10019909" />
    </Mention>
    <Mention id="M413" len="29" reason="from_drug_use" section="S1" start="31383" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thyroid function test abnormal" meddra_llt_id="10043730" meddra_pt="Thyroid function test abnormal" meddra_pt_id="10043730" />
    </Mention>
    <Mention id="M414" len="10" reason="from_drug_use" section="S1" start="31414" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Moniliasis" meddra_llt_id="10027825" meddra_pt="Candida infection" meddra_pt_id="10074170" />
    </Mention>
    <Mention id="M415" len="25" reason="from_drug_use" section="S1" start="31426" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Photosensitivity reaction" meddra_llt_id="10034972" meddra_pt="Photosensitivity reaction" meddra_pt_id="10034972" />
    </Mention>
    <Mention id="M416" len="7" reason="from_drug_use" section="S1" start="31453" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sarcoma" meddra_llt_id="10039491" meddra_pt="Sarcoma" meddra_pt_id="10039491" />
    </Mention>
    <Mention id="M417" len="6" reason="from_drug_use" section="S1" start="31462" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sepsis" meddra_llt_id="10040047" meddra_pt="Sepsis" meddra_pt_id="10040047" />
    </Mention>
    <Mention id="M418" len="15" reason="from_drug_use" section="S1" start="31470" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection viral" meddra_llt_id="10021876" meddra_pt="Viral infection" meddra_pt_id="10047461" />
      <Normalization meddra_pt="Infection reactivation" meddra_pt_id="10070891" />
    </Mention>
    <Mention id="M76" len="21" reason="general_term" section="S1" start="31491" type="NonOSE_AE">
      <Normalization meddra_llt="Symptoms involving cardiovascular system" meddra_llt_id="10042758" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M419" len="15" reason="from_drug_use" section="S1" start="31515" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angina pectoris" meddra_llt_id="10002383" meddra_pt="Angina pectoris" meddra_pt_id="10002383" />
    </Mention>
    <Mention id="M420" len="10" reason="from_drug_use" section="S1" start="31532" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arrhythmia" meddra_llt_id="10003119" meddra_pt="Arrhythmia" meddra_pt_id="10003119" />
    </Mention>
    <Mention id="M421" len="19" reason="from_drug_use" section="S1" start="31544" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Atrial fibrillation" meddra_llt_id="10003658" meddra_pt="Atrial fibrillation" meddra_pt_id="10003658" />
    </Mention>
    <Mention id="M422" len="11" reason="from_drug_use" section="S1" start="31565" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M423" len="17" reason="from_drug_use" section="S1" start="31578" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ischemia cerebral" meddra_llt_id="10023029" meddra_pt="Cerebral ischaemia" meddra_pt_id="10008120" />
    </Mention>
    <Mention id="M424" len="24" reason="from_drug_use" section="S1" start="31597" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Accident cerebrovascular" meddra_llt_id="10000374" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M425" len="24" reason="from_drug_use" section="S1" start="31623" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Congestive heart failure" meddra_llt_id="10010684" meddra_pt="Cardiac failure congestive" meddra_pt_id="10007559" />
    </Mention>
    <Mention id="M426" len="21" reason="from_drug_use" section="S1" start="31649" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombophlebitis deep" meddra_llt_id="10043575" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M427" len="12" reason="from_drug_use" section="S1" start="31672" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart arrest" meddra_llt_id="10019249" meddra_pt="Cardiac arrest" meddra_pt_id="10007515" />
    </Mention>
    <Mention id="M428" len="13" reason="from_drug_use" section="S1" start="31686" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M429" len="12" reason="from_drug_use" section="S1" start="31701" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M430" len="11" reason="from_drug_use" section="S1" start="31715" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M431" len="6" reason="from_drug_use" section="S1" start="31728" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Holosystolic murmur" meddra_llt_id="10050566" meddra_pt="Cardiac murmur" meddra_pt_id="10007586" />
    </Mention>
    <Mention id="M432" len="18" reason="from_drug_use" section="S1" start="31736" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial infarct" meddra_llt_id="10028595" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M433" len="11" reason="from_drug_use" section="S1" start="31756" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Palpitation" meddra_llt_id="10033556" meddra_pt="Palpitations" meddra_pt_id="10033557" />
    </Mention>
    <Mention id="M434" len="12" reason="from_drug_use" section="S1" start="31769" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pericarditis" meddra_llt_id="10034484" meddra_pt="Pericarditis" meddra_pt_id="10034484" />
    </Mention>
    <Mention id="M435" len="28" reason="from_drug_use" section="S1" start="31783" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder peripheral vascular" meddra_llt_id="10013255" meddra_pt="Peripheral vascular disorder" meddra_pt_id="10034636" />
    </Mention>
    <Mention id="M436" len="20" reason="from_drug_use" section="S1" start="31813" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Postural hypotension" meddra_llt_id="10036433" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M437" len="7" reason="from_drug_use" section="S1" start="31835" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M438" len="11" reason="from_drug_use" section="S1" start="31844" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M439" len="16" reason="from_drug_use" section="S1" start="31857" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombophlebitis" meddra_llt_id="10043570" meddra_pt="Thrombophlebitis" meddra_pt_id="10043570" />
    </Mention>
    <Mention id="M440" len="10" reason="from_drug_use" section="S1" start="31875" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombosis" meddra_llt_id="10043607" meddra_pt="Thrombosis" meddra_pt_id="10043607" />
    </Mention>
    <Mention id="M77" len="16" reason="general_term" section="S1" start="31891" type="NonOSE_AE">
      <Normalization meddra_llt="Symptoms involving digestive system" meddra_llt_id="10042759" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M441" len="11" reason="from_drug_use" section="S1" start="31910" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cholangitis" meddra_llt_id="10008604" meddra_pt="Cholangitis" meddra_pt_id="10008604" />
    </Mention>
    <Mention id="M442" len="20" reason="from_drug_use" section="S1" start="31923" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cholestatic jaundice" meddra_llt_id="10008640" meddra_pt="Jaundice cholestatic" meddra_pt_id="10023129" />
    </Mention>
    <Mention id="M443" len="7" reason="from_drug_use" section="S1" start="31945" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Colitis" meddra_llt_id="10009887" meddra_pt="Colitis" meddra_pt_id="10009887" />
    </Mention>
    <Mention id="M444" len="9" reason="from_drug_use" section="S1" start="31954" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M445" len="9" reason="from_drug_use" section="S1" start="31965" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysphagia" meddra_llt_id="10013950" meddra_pt="Dysphagia" meddra_pt_id="10013950" />
    </Mention>
    <Mention id="M446" len="11" reason="from_drug_use" section="S1" start="31976" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Esophagitis" meddra_llt_id="10015461" meddra_pt="Oesophagitis" meddra_pt_id="10030216" />
    </Mention>
    <Mention id="M447" len="15" reason="from_drug_use" section="S1" start="31989" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastroenteritis" meddra_llt_id="10017888" meddra_pt="Gastroenteritis" meddra_pt_id="10017888" />
    </Mention>
    <Mention id="M448" len="25" reason="from_drug_use" section="S1" start="32006" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M449" len="27" reason="from_drug_use" section="S1" start="32033" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemorrhage gastrointestinal" meddra_llt_id="10019543" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M450" len="12" reason="from_drug_use" section="S1" start="32062" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gum disorder" meddra_llt_id="10018775" meddra_pt="Gingival disorder" meddra_pt_id="10018280" />
    </Mention>
    <Mention id="M451" len="9" reason="from_drug_use" section="S1" start="32076" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatitis" meddra_llt_id="10019717" meddra_pt="Hepatitis" meddra_pt_id="10019717" />
    </Mention>
    <Mention id="M452" len="12" reason="from_drug_use" section="S1" start="32087" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pancreatitis" meddra_llt_id="10033645" meddra_pt="Pancreatitis" meddra_pt_id="10033645" />
    </Mention>
    <Mention id="M453" len="25" reason="from_drug_use" section="S1" start="32101" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Enlargement parotid gland" meddra_llt_id="10014850" meddra_pt="Parotid gland enlargement" meddra_pt_id="10034023" />
    </Mention>
    <Mention id="M454" len="13" reason="from_drug_use" section="S1" start="32128" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Periodontitis" meddra_llt_id="10034539" meddra_pt="Periodontitis" meddra_pt_id="10034539" />
    </Mention>
    <Mention id="M455" len="10" reason="from_drug_use" section="S1" start="32143" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomatitis" meddra_llt_id="10042128" meddra_pt="Stomatitis" meddra_pt_id="10042128" />
    </Mention>
    <Mention id="M456" len="20" reason="from_drug_use" section="S1" start="32155" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tongue discoloration" meddra_llt_id="10043948" meddra_pt="Tongue discolouration" meddra_pt_id="10043949" />
    </Mention>
    <Mention id="M457" len="14" reason="from_drug_use" section="S1" start="32177" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tooth disorder" meddra_llt_id="10044034" meddra_pt="Tooth disorder" meddra_pt_id="10044034" />
    </Mention>
    <Mention id="M78" len="23" reason="general_term" section="S1" start="32197" type="NonOSE_AE">
      <Normalization meddra_llt="Other transitory neonatal endocrine and metabolic disturbances" meddra_llt_id="10033002" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M458" len="12" reason="from_drug_use" section="S1" start="32223" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Avitaminosis" meddra_llt_id="10003862" meddra_pt="Hypovitaminosis" meddra_pt_id="10021135" />
    </Mention>
    <Mention id="M459" len="13" reason="from_drug_use" section="S1" start="32237" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bilirubinemia" meddra_llt_id="10004705" meddra_pt="Hyperbilirubinaemia" meddra_pt_id="10020578" />
    </Mention>
    <Mention id="M460" len="11" reason="from_drug_use" section="S1" start="32252" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M461" len="20" reason="from_drug_use" section="S1" start="32265" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypercholesterolemia" meddra_llt_id="10020604" meddra_pt="Hypercholesterolaemia" meddra_pt_id="10020603" />
    </Mention>
    <Mention id="M462" len="12" reason="from_drug_use" section="S1" start="32287" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypoglycemia" meddra_llt_id="10021005" meddra_pt="Hypoglycaemia" meddra_pt_id="10020993" />
    </Mention>
    <Mention id="M463" len="30" reason="from_drug_use" section="S1" start="32301" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alkaline phosphatase increased" meddra_llt_id="10001675" meddra_pt="Blood alkaline phosphatase increased" meddra_pt_id="10059570" />
    </Mention>
    <Mention id="M464" len="16" reason="from_drug_use" section="S1" start="32333" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lipase increased" meddra_llt_id="10024574" meddra_pt="Lipase increased" meddra_pt_id="10024574" />
    </Mention>
    <Mention id="M465" len="26" reason="from_drug_use" section="S1" start="32351" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Creatinine serum increased" meddra_llt_id="10011375" meddra_pt="Blood creatinine increased" meddra_pt_id="10005483" />
    </Mention>
    <Mention id="M466" len="16" reason="from_drug_use" section="S1" start="32379" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral edema" meddra_llt_id="10034570" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" />
    </Mention>
    <Mention id="M79" len="17" reason="general_term" section="S1" start="32401" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal degeneration" meddra_llt_id="10074400" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M467" len="7" reason="from_drug_use" section="S1" start="32421" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M468" len="10" reason="from_drug_use" section="S1" start="32430" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myasthenia" meddra_llt_id="10028415" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M80" len="14" reason="general_term" section="S1" start="32446" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder nervous system" meddra_llt_id="10013242" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M469" len="13" reason="from_drug_use" section="S1" start="32463" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abnormal gait" meddra_llt_id="10000136" meddra_pt="Gait disturbance" meddra_pt_id="10017577" />
    </Mention>
    <Mention id="M470" len="6" reason="from_drug_use" section="S1" start="32478" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ataxia" meddra_llt_id="10003591" meddra_pt="Ataxia" meddra_pt_id="10003591" />
    </Mention>
    <Mention id="M471" len="16" reason="from_drug_use" section="S1" start="32486" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Libido decreased" meddra_llt_id="10024419" meddra_pt="Libido decreased" meddra_pt_id="10024419" />
    </Mention>
    <Mention id="M472" len="18" reason="from_drug_use" section="S1" start="32504" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Reflexes decreased" meddra_llt_id="10038257" meddra_pt="Hyporeflexia" meddra_pt_id="10021089" />
    </Mention>
    <Mention id="M473" len="8" reason="from_drug_use" section="S1" start="32524" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M474" len="11" reason="from_drug_use" section="S1" start="32534" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysesthesia" meddra_llt_id="10062872" meddra_pt="Dysaesthesia" meddra_pt_id="10013886" />
    </Mention>
    <Mention id="M475" len="10" reason="from_drug_use" section="S1" start="32547" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyskinesia" meddra_llt_id="10013916" meddra_pt="Dyskinesia" meddra_pt_id="10013916" />
    </Mention>
    <Mention id="M476" len="18" reason="from_drug_use" section="S1" start="32559" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Emotional lability" meddra_llt_id="10014555" meddra_pt="Affect lability" meddra_pt_id="10054196" />
    </Mention>
    <Mention id="M477" len="9" reason="from_drug_use" section="S1" start="32579" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hostility" meddra_llt_id="10020400" meddra_pt="Hostility" meddra_pt_id="10020400" />
    </Mention>
    <Mention id="M478" len="10" reason="from_drug_use" section="S1" start="32590" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypalgesia" meddra_llt_id="10020549" meddra_pt="Hypoaesthesia" meddra_pt_id="10020937" />
    </Mention>
    <Mention id="M479" len="12" reason="from_drug_use" section="S1" start="32602" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperkinesia" meddra_llt_id="10020651" meddra_pt="Hyperkinesia" meddra_pt_id="10020651" />
    </Mention>
    <Mention id="M480" len="14" reason="from_drug_use" section="S1" start="32616" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Incoordination" meddra_llt_id="10021649" meddra_pt="Coordination abnormal" meddra_pt_id="10010947" />
    </Mention>
    <Mention id="M481" len="10" reason="from_drug_use" section="S1" start="32632" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Meningitis" meddra_llt_id="10027199" meddra_pt="Meningitis" meddra_pt_id="10027199" />
    </Mention>
    <Mention id="M482" len="19" reason="from_drug_use" section="S1" start="32644" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neurologic disorder NOS" meddra_llt_id="10029286" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M483" len="6" reason="from_drug_use" section="S1" start="32665" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M484" len="7" reason="from_drug_use" section="S1" start="32673" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M81" len="18" reason="general_term" section="S1" start="32686" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder respiratory system" meddra_llt_id="10013264" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M485" len="5" reason="from_drug_use" section="S1" start="32707" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Apnea" meddra_llt_id="10002972" meddra_pt="Apnoea" meddra_pt_id="10002974" />
    </Mention>
    <Mention id="M486" len="10" reason="from_drug_use" section="S1" start="32714" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchitis" meddra_llt_id="10006451" meddra_pt="Bronchitis" meddra_pt_id="10006451" />
    </Mention>
    <Mention id="M487" len="13" reason="from_drug_use" section="S1" start="32726" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder lung" meddra_llt_id="10013235" meddra_pt="Lung disorder" meddra_pt_id="10025082" />
    </Mention>
    <Mention id="M488" len="10" reason="from_drug_use" section="S1" start="32741" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lung edema" meddra_llt_id="10025084" meddra_pt="Pulmonary oedema" meddra_pt_id="10037423" />
    </Mention>
    <Mention id="M489" len="9" reason="from_drug_use" section="S1" start="32753" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pneumonia" meddra_llt_id="10035664" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M490" len="30" reason="from_drug_use" section="S1" start="32774" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pneumocystis carinii pneumonia" meddra_llt_id="10035659" meddra_pt="Pneumocystis jirovecii pneumonia" meddra_pt_id="10073755" />
    </Mention>
    <Mention id="M491" len="8" reason="from_drug_use" section="S1" start="32807" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rhinitis" meddra_llt_id="10039083" meddra_pt="Rhinitis" meddra_pt_id="10039083" />
    </Mention>
    <Mention id="M82" len="19" reason="general_term" section="S1" start="32821" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M492" len="10" reason="from_drug_use" section="S1" start="32843" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M493" len="20" reason="from_drug_use" section="S1" start="32855" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin benign neoplasm" meddra_llt_id="10040802" meddra_pt="Benign neoplasm of skin" meddra_pt_id="10004398" />
    </Mention>
    <Mention id="M494" len="6" reason="from_drug_use" section="S1" start="32877" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eczema" meddra_llt_id="10014184" meddra_pt="Eczema" meddra_pt_id="10014184" />
    </Mention>
    <Mention id="M495" len="14" reason="from_drug_use" section="S1" start="32885" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Herpes simplex" meddra_llt_id="10019948" meddra_pt="Herpes simplex" meddra_pt_id="10019948" />
    </Mention>
    <Mention id="M496" len="24" reason="from_drug_use" section="S1" start="32912" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syndrome Stevens-Johnson" meddra_llt_id="10042849" meddra_pt="Stevens-Johnson syndrome" meddra_pt_id="10042033" />
    </Mention>
    <Mention id="M497" len="13" reason="from_drug_use" section="S1" start="32938" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nail disorder" meddra_llt_id="10028694" meddra_pt="Nail disorder" meddra_pt_id="10028694" />
    </Mention>
    <Mention id="M498" len="8" reason="from_drug_use" section="S1" start="32953" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M499" len="9" reason="from_drug_use" section="S1" start="32963" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psoriasis" meddra_llt_id="10037153" meddra_pt="Psoriasis" meddra_pt_id="10037153" />
    </Mention>
    <Mention id="M500" len="18" reason="from_drug_use" section="S1" start="32974" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discoloration skin" meddra_llt_id="10013076" meddra_pt="Skin discolouration" meddra_pt_id="10040829" />
    </Mention>
    <Mention id="M501" len="13" reason="from_drug_use" section="S1" start="32994" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M83" len="14" reason="general_term" section="S1" start="33013" type="NonOSE_AE">
      <Normalization meddra_llt="Cranial nerve disorder" meddra_llt_id="10061093" meddra_pt="Cranial nerve disorder" meddra_pt_id="10061093" />
    </Mention>
    <Mention id="M502" len="14" reason="from_drug_use" section="S1" start="33030" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Conjunctivitis" meddra_llt_id="10010741" meddra_pt="Conjunctivitis" meddra_pt_id="10010741" />
    </Mention>
    <Mention id="M503" len="12" reason="from_drug_use" section="S1" start="33046" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M504" len="20" reason="from_drug_use" section="S1" start="33060" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder lacrimation" meddra_llt_id="10013233" meddra_pt="Lacrimation disorder" meddra_pt_id="10023643" />
    </Mention>
    <Mention id="M505" len="9" reason="from_drug_use" section="S1" start="33082" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Retinitis" meddra_llt_id="10038910" meddra_pt="Retinitis" meddra_pt_id="10038910" />
    </Mention>
    <Mention id="M506" len="16" reason="from_drug_use" section="S1" start="33093" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Taste perversion" meddra_llt_id="10043137" meddra_pt="Dysgeusia" meddra_pt_id="10013911" />
    </Mention>
    <Mention id="M84" len="19" reason="general_term" section="S1" start="33550" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified diseases of blood and blood-forming organs" meddra_llt_id="10045763" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M507" len="33" reason="from_drug_use" section="S1" start="33572" type="OSE_Labeled_AE">
      <Normalization meddra_llt="White blood cell count decreased" meddra_llt_id="10047942" meddra_pt="White blood cell count decreased" meddra_pt_id="10047942" />
    </Mention>
    <Mention id="M508" len="19" reason="from_drug_use" section="S1" start="33616" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Febrile neutropenia" meddra_llt_id="10016288" meddra_pt="Febrile neutropenia" meddra_pt_id="10016288" />
    </Mention>
    <Mention id="M509" len="27" reason="from_drug_use" section="S1" start="33637" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Prothrombin time abnormal" meddra_llt_id="10037057" meddra_pt="Prothrombin time abnormal" meddra_pt_id="10037057" />
    </Mention>
    <Mention id="M510" len="12" reason="from_drug_use" section="S1" start="33666" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pancytopenia" meddra_llt_id="10033661" meddra_pt="Pancytopenia" meddra_pt_id="10033661" />
    </Mention>
    <Mention id="M511" len="28" reason="from_drug_use" section="S1" start="33680" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Chronic myelogenous leukemia" meddra_llt_id="10009012" meddra_pt="Chronic myeloid leukaemia" meddra_pt_id="10009013" />
    </Mention>
    <Mention id="M512" len="36" reason="from_drug_use" section="S1" start="33710" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hodgkin's disease nodular sclerosis" meddra_llt_id="10020244" meddra_pt="Hodgkin's disease nodular sclerosis" meddra_pt_id="10020244" />
    </Mention>
    <Mention id="M513" len="15" reason="from_drug_use" section="S1" start="33748" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythroleukemia" meddra_llt_id="10015282" meddra_pt="Erythroleukaemia" meddra_pt_id="10015281" />
    </Mention>
    <Mention id="M514" len="10" reason="from_drug_use" section="S1" start="33765" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lymphedema" meddra_llt_id="10025233" meddra_pt="Lymphoedema" meddra_pt_id="10025282" />
    </Mention>
    <Mention id="M515" len="11" reason="from_drug_use" section="S1" start="33777" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lymphopenia" meddra_llt_id="10025327" meddra_pt="Lymphopenia" meddra_pt_id="10025327" />
    </Mention>
    <Mention id="M85" len="15" reason="general_term" section="S1" start="33794" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M516" len="15" reason="from_drug_use" section="S1" start="33812" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hangover effect" meddra_llt_id="10019136" meddra_pt="Hangover" meddra_pt_id="10019133" />
    </Mention>
    <Mention id="M86" len="21" reason="general_term" section="S1" start="33832" type="NonOSE_AE">
      <Normalization meddra_llt="Symptoms involving cardiovascular system" meddra_llt_id="10042758" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M517" len="19" reason="from_drug_use" section="S1" start="33856" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syndrome sick sinus" meddra_llt_id="10042845" meddra_pt="Sinus node dysfunction" meddra_pt_id="10075889" />
    </Mention>
    <Mention id="M518" len="17" reason="from_drug_use" section="S1" start="33877" type="OSE_Labeled_AE">
      <Normalization meddra_llt="EKG/ECG abnormalities non-specific" meddra_llt_id="10014336" meddra_pt="Electrocardiogram abnormal" meddra_pt_id="10014363" />
    </Mention>
    <Mention id="M519" len="22" reason="from_drug_use" section="S1" start="33896" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary hypertension" meddra_llt_id="10037400" meddra_pt="Pulmonary hypertension" meddra_pt_id="10037400" />
    </Mention>
    <Mention id="M87" len="16" reason="general_term" section="S1" start="33924" type="NonOSE_AE">
      <Normalization meddra_llt="Symptoms involving digestive system" meddra_llt_id="10042759" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M520" len="22" reason="from_drug_use" section="S1" start="33943" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Perforation intestinal" meddra_llt_id="10034413" meddra_pt="Intestinal perforation" meddra_pt_id="10022694" />
    </Mention>
    <Mention id="M521" len="29" reason="from_drug_use" section="S1" start="33967" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastrointestinal perforation" meddra_llt_id="10018001" meddra_pt="Gastrointestinal perforation" meddra_pt_id="10018001" />
    </Mention>
    <Mention id="M522" len="21" reason="from_drug_use" section="S1" start="33998" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bile duct obstruction" meddra_llt_id="10056375" meddra_pt="Bile duct obstruction" meddra_pt_id="10056375" />
    </Mention>
    <Mention id="M523" len="13" reason="from_drug_use" section="S1" start="34021" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomach ulcer" meddra_llt_id="10042116" meddra_pt="Gastric ulcer" meddra_pt_id="10017822" />
    </Mention>
    <Mention id="M524" len="8" reason="from_drug_use" section="S1" start="34036" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ulcer aphthous" meddra_llt_id="10045287" meddra_pt="Aphthous ulcer" meddra_pt_id="10002959" />
    </Mention>
    <Mention id="M525" len="10" reason="from_drug_use" section="S1" start="34046" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomatitis" meddra_llt_id="10042128" meddra_pt="Stomatitis" meddra_pt_id="10042128" />
    </Mention>
    <Mention id="M88" len="30" reason="general_term" section="S1" start="34062" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder ear" meddra_llt_id="10013214" meddra_pt="Ear disorder" meddra_pt_id="10014004" />
    </Mention>
    <Mention id="M526" len="18" reason="from_drug_use" section="S1" start="34095" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hearing impairment aggravated" meddra_llt_id="10048394" meddra_pt="Hypoacusis" meddra_pt_id="10048865" />
    </Mention>
    <Mention id="M89" len="23" reason="general_term" section="S1" start="34119" type="NonOSE_AE">
      <Normalization meddra_llt="Immune system disorder" meddra_llt_id="10021425" meddra_pt="Immune system disorder" meddra_pt_id="10021425" />
    </Mention>
    <Mention id="M527" len="16" reason="from_drug_use" section="S1" start="34145" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M90" len="27" reason="general_term" section="S1" start="34167" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M604" len="10" reason="from_drug_use" section="S1" start="34204" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M93" len="5" reason="general_term" section="S1" start="34222" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M605" len="6" reason="from_drug_use" section="S1" start="34228" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sepsis" meddra_llt_id="10040047" meddra_pt="Sepsis" meddra_pt_id="10040047" />
    </Mention>
    <Mention id="M528" len="12" reason="from_drug_use" section="S1" start="34245" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Septic shock" meddra_llt_id="10040070" meddra_pt="Septic shock" meddra_pt_id="10040070" />
    </Mention>
    <Mention id="M529" len="16" reason="from_drug_use" section="S1" start="34263" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection viral" meddra_llt_id="10021876" meddra_pt="Viral infection" meddra_pt_id="10047461" />
      <Normalization meddra_pt="Infection reactivation" meddra_pt_id="10070891" />
    </Mention>
    <Mention id="M530" len="22" reason="from_drug_use" section="S1" start="34291" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Varicella zoster virus infection" meddra_llt_id="10075611" meddra_pt="Varicella zoster virus infection" meddra_pt_id="10075611" />
    </Mention>
    <Mention id="M531" len="15" reason="from_drug_use" section="S1" start="34315" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cytomegalovirus infection" meddra_llt_id="10011831" meddra_pt="Cytomegalovirus infection" meddra_pt_id="10011831" />
    </Mention>
    <Mention id="M532" len="30" reason="from_drug_use" section="S1" start="34336" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatitis B reactivation" meddra_llt_id="10058827" meddra_pt="Hepatitis B reactivation" meddra_pt_id="10058827" />
    </Mention>
    <Mention id="M91" len="23" reason="general_term" section="S1" start="34373" type="NonOSE_AE">
      <Normalization meddra_llt="Other transitory neonatal endocrine and metabolic disturbances" meddra_llt_id="10033002" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M606" len="21" reason="from_drug_use" section="S1" start="34399" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Electrolyte imbalance" meddra_llt_id="10014418" meddra_pt="Electrolyte imbalance" meddra_pt_id="10014418" />
      <Normalization meddra_pt="Blood electrolytes abnormal" meddra_pt_id="10061014" />
    </Mention>
    <Mention id="M533" len="13" reason="from_drug_use" section="S1" start="34431" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypercalcemia" meddra_llt_id="10020587" meddra_pt="Hypercalcaemia" meddra_pt_id="10020583" />
    </Mention>
    <Mention id="M534" len="12" reason="from_drug_use" section="S1" start="34446" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyponatremia" meddra_llt_id="10021038" meddra_pt="Hyponatraemia" meddra_pt_id="10021036" />
    </Mention>
    <Mention id="M535" len="14" reason="from_drug_use" section="S1" start="34463" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypomagnesemia" meddra_llt_id="10021028" meddra_pt="Hypomagnesaemia" meddra_pt_id="10021027" />
    </Mention>
    <Mention id="M536" len="14" reason="from_drug_use" section="S1" start="34479" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypothyroidism" meddra_llt_id="10021114" meddra_pt="Hypothyroidism" meddra_pt_id="10021114" />
    </Mention>
    <Mention id="M537" len="30" reason="from_drug_use" section="S1" start="34495" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alkaline phosphatase increased" meddra_llt_id="10001675" meddra_pt="Blood alkaline phosphatase increased" meddra_pt_id="10059570" />
    </Mention>
    <Mention id="M538" len="20" reason="from_drug_use" section="S1" start="34527" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tumor lysis syndrome" meddra_llt_id="10045152" meddra_pt="Tumour lysis syndrome" meddra_pt_id="10045170" />
    </Mention>
    <Mention id="M539" len="8" reason="from_drug_use" section="S1" start="34549" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myxedema" meddra_llt_id="10028663" meddra_pt="Myxoedema" meddra_pt_id="10028665" />
    </Mention>
    <Mention id="M92" len="14" reason="general_term" section="S1" start="34563" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder nervous system" meddra_llt_id="10013242" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M540" len="24" reason="from_drug_use" section="S1" start="34580" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mental status changes" meddra_llt_id="10048294" meddra_pt="Mental status changes" meddra_pt_id="10048294" />
    </Mention>
    <Mention id="M541" len="32" reason="from_drug_use" section="S1" start="34580" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mood altered" meddra_llt_id="10027940" meddra_pt="Mood altered" meddra_pt_id="10027940" />
    </Mention>
    <Mention id="M542" len="16" reason="from_drug_use" section="S1" start="34623" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Suicide attempt" meddra_llt_id="10042464" meddra_pt="Suicide attempt" meddra_pt_id="10042464" />
    </Mention>
    <Mention id="M543" len="29" reason="from_drug_use" section="S1" start="34641" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Consciousness abnormal" meddra_llt_id="10010765" meddra_pt="Altered state of consciousness" meddra_pt_id="10001854" />
    </Mention>
    <Mention id="M544" len="8" reason="from_drug_use" section="S1" start="34681" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M545" len="21" reason="from_drug_use" section="S1" start="34691" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Consciousness loss of" meddra_llt_id="10010772" meddra_pt="Loss of consciousness" meddra_pt_id="10024855" />
    </Mention>
    <Mention id="M546" len="6" reason="from_drug_use" section="S1" start="34716" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stupor" meddra_llt_id="10042264" meddra_pt="Stupor" meddra_pt_id="10042264" />
    </Mention>
    <Mention id="M547" len="8" reason="from_drug_use" section="S1" start="34724" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M548" len="21" reason="from_drug_use" section="S1" start="34743" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Convulsions grand mal" meddra_llt_id="10010918" meddra_pt="Generalised tonic-clonic seizure" meddra_pt_id="10018100" />
    </Mention>
    <Mention id="M549" len="18" reason="from_drug_use" section="S1" start="34769" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Status epilepticus" meddra_llt_id="10041962" meddra_pt="Status epilepticus" meddra_pt_id="10041962" />
    </Mention>
    <Mention id="M550" len="19" reason="from_drug_use" section="S1" start="34789" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinson's disease" meddra_llt_id="10061536" meddra_pt="Parkinson's disease" meddra_pt_id="10061536" />
    </Mention>
    <Mention id="M551" len="6" reason="from_drug_use" section="S1" start="34810" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M552" len="13" reason="from_drug_use" section="S1" start="34818" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Carpal tunnel syndrome" meddra_llt_id="10007697" meddra_pt="Carpal tunnel syndrome" meddra_pt_id="10007697" />
    </Mention>
    <Mention id="M553" len="18" reason="from_drug_use" section="S1" start="34833" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Raynaud's syndrome" meddra_llt_id="10037914" meddra_pt="Raynaud's phenomenon" meddra_pt_id="10037912" />
    </Mention>
    <Mention id="M554" len="8" reason="from_drug_use" section="S1" start="34853" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Migraine" meddra_llt_id="10027599" meddra_pt="Migraine" meddra_pt_id="10027599" />
    </Mention>
    <Mention id="M555" len="9" reason="from_drug_use" section="S1" start="34863" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Foot drop" meddra_llt_id="10016967" meddra_pt="Peroneal nerve palsy" meddra_pt_id="10034701" />
    </Mention>
    <Mention id="M94" len="27" reason="general_term" section="S1" start="34878" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder renal" meddra_llt_id="10013263" meddra_pt="Renal disorder" meddra_pt_id="10038428" />
    </Mention>
    <Mention id="M556" len="13" reason="from_drug_use" section="S1" start="34908" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Renal failure" meddra_llt_id="10038435" meddra_pt="Renal failure" meddra_pt_id="10038435" />
    </Mention>
    <Mention id="M557" len="19" reason="from_drug_use" section="S1" start="34923" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Renal failure acute" meddra_llt_id="10038436" meddra_pt="Acute kidney injury" meddra_pt_id="10069339" />
    </Mention>
    <Mention id="M558" len="8" reason="from_drug_use" section="S1" start="34944" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oliguria" meddra_llt_id="10030302" meddra_pt="Oliguria" meddra_pt_id="10030302" />
    </Mention>
    <Mention id="M559" len="8" reason="from_drug_use" section="S1" start="34954" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Enuresis" meddra_llt_id="10014928" meddra_pt="Enuresis" meddra_pt_id="10014928" />
    </Mention>
    <Mention id="M95" len="40" reason="general_term" section="S1" start="34968" type="NonOSE_AE">
      <Normalization meddra_llt="Reproductive tract disorder" meddra_llt_id="10061483" meddra_pt="Reproductive tract disorder" meddra_pt_id="10061483" />
      <Normalization meddra_pt="Reproductive toxicity" meddra_pt_id="10074268" />
    </Mention>
    <Mention id="M560" len="10" reason="from_drug_use" section="S1" start="35011" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amenorrhea" meddra_llt_id="10001927" meddra_pt="Amenorrhoea" meddra_pt_id="10001928" />
    </Mention>
    <Mention id="M561" len="18" reason="from_drug_use" section="S1" start="35023" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sexual dysfunction" meddra_llt_id="10040477" meddra_pt="Sexual dysfunction" meddra_pt_id="10040477" />
    </Mention>
    <Mention id="M562" len="12" reason="from_drug_use" section="S1" start="35043" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Galactorrhea" meddra_llt_id="10017592" meddra_pt="Galactorrhoea" meddra_pt_id="10017600" />
    </Mention>
    <Mention id="M563" len="12" reason="from_drug_use" section="S1" start="35057" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gynecomastia" meddra_llt_id="10018801" meddra_pt="Gynaecomastia" meddra_pt_id="10018800" />
    </Mention>
    <Mention id="M564" len="12" reason="from_drug_use" section="S1" start="35071" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Metrorrhagia" meddra_llt_id="10027514" meddra_pt="Metrorrhagia" meddra_pt_id="10027514" />
    </Mention>
    <Mention id="M96" len="18" reason="general_term" section="S1" start="35089" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder respiratory system" meddra_llt_id="10013264" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M565" len="16" reason="from_drug_use" section="S1" start="35110" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Effusion pleural" meddra_llt_id="10014313" meddra_pt="Pleural effusion" meddra_pt_id="10035598" />
    </Mention>
    <Mention id="M566" len="25" reason="from_drug_use" section="S1" start="35128" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Interstitial lung disease" meddra_llt_id="10022611" meddra_pt="Interstitial lung disease" meddra_pt_id="10022611" />
    </Mention>
    <Mention id="M97" len="19" reason="general_term" section="S1" start="35159" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M567" len="19" reason="from_drug_use" section="S1" start="35181" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythema multiforme" meddra_llt_id="10015218" meddra_pt="Erythema multiforme" meddra_pt_id="10015218" />
    </Mention>
    <Mention id="M568" len="16" reason="from_drug_use" section="S1" start="35202" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythema nodosum" meddra_llt_id="10015226" meddra_pt="Erythema nodosum" meddra_pt_id="10015226" />
    </Mention>
    <Mention id="M569" len="26" reason="from_drug_use" section="S1" start="35220" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxic epidermal necrolysis" meddra_llt_id="10044223" meddra_pt="Toxic epidermal necrolysis" meddra_pt_id="10044223" />
    </Mention>
    <Mention id="M570" len="7" reason="from_drug_use" section="S1" start="35248" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Purpura" meddra_llt_id="10037549" meddra_pt="Purpura" meddra_pt_id="10037549" />
    </Mention>
    <Mention id="M571" len="9" reason="from_drug_use" section="S1" start="35257" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Petechiae" meddra_llt_id="10034754" meddra_pt="Petechiae" meddra_pt_id="10034754" />
    </Mention>
    <Mention id="M98" len="14" reason="general_term" section="S1" start="35272" type="NonOSE_AE">
      <Normalization meddra_llt="Cranial nerve disorder" meddra_llt_id="10061093" meddra_pt="Cranial nerve disorder" meddra_pt_id="10061093" />
    </Mention>
    <Mention id="M572" len="8" reason="from_drug_use" section="S1" start="35289" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diplopia" meddra_llt_id="10013036" meddra_pt="Diplopia" meddra_pt_id="10013036" />
    </Mention>
    <Mention id="M573" len="9" reason="from_drug_use" section="S1" start="35299" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nystagmus" meddra_llt_id="10029864" meddra_pt="Nystagmus" meddra_pt_id="10029864" />
    </Mention>
    <Mention id="M624" len="21" reason="from_drug_use" section="S2" start="91" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M607" len="9" reason="preexisting_condition_or_risk_factor" section="S2" start="150" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M625" len="13" reason="from_drug_use" section="S2" start="181" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Birth defects" meddra_llt_id="10048305" meddra_pt="Congenital anomaly" meddra_pt_id="10010356" />
      <Normalization meddra_pt="Congenital anomaly in offspring" meddra_pt_id="10063726" />
    </Mention>
    <Mention id="M619" len="18" reason="from_drug_use" section="S2" start="198" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Death fetal" meddra_llt_id="10011908" meddra_pt="Foetal death" meddra_pt_id="10055690" />
    </Mention>
    <Mention id="M608" len="8" reason="contraindication" section="S2" start="270" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M618" len="8" reason="AE_only_as_instruction" section="S2" start="299" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M609" len="8" reason="preexisting_condition_or_risk_factor" section="S2" start="398" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M610" len="9" reason="preexisting_condition_or_risk_factor" section="S2" start="424" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M620" len="13" reason="from_drug_use" section="S2" start="451" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Birth defects" meddra_llt_id="10048305" meddra_pt="Congenital anomaly" meddra_pt_id="10010356" />
      <Normalization meddra_pt="Congenital anomaly in offspring" meddra_pt_id="10063726" />
    </Mention>
    <Mention id="M617" len="33" reason="AE_only_as_instruction" section="S2" start="536" type="NonOSE_AE">
      <Normalization meddra_llt="Maternal drugs affecting fetus" meddra_llt_id="10060521" meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
      <Normalization meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
    </Mention>
    <Mention id="M611" len="16" reason="indication" section="S2" start="1079" type="Not_AE_Candidate">
      <Normalization meddra_llt="Multiple myeloma" meddra_llt_id="10028228" meddra_pt="Plasma cell myeloma" meddra_pt_id="10035226" />
    </Mention>
    <Mention id="M621" len="22" reason="from_drug_use" section="S2" start="1128" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M622" len="22" reason="from_drug_use" section="S2" start="1160" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombosis venous deep" meddra_llt_id="10043642" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M626" len="18" reason="from_drug_use" section="S2" start="1187" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary embolism" meddra_llt_id="10037377" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M623" len="22" reason="from_drug_use" section="S2" start="1382" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M612" len="15" reason="AE_only_as_instruction" section="S2" start="1637" type="NonOSE_AE">
      <Normalization meddra_llt="Thromboembolism" meddra_llt_id="10043566" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M613" len="19" reason="manifestation_or_complication" section="S2" start="1726" type="NonOSE_AE">
      <Normalization meddra_llt="Shortness of breath" meddra_llt_id="10040604" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M614" len="10" reason="manifestation_or_complication" section="S2" start="1747" type="NonOSE_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M615" len="3,8" reason="manifestation_or_complication" section="S2" start="1762,1773" type="NonOSE_AE">
      <Normalization meddra_llt="Swelling arm" meddra_llt_id="10042680" meddra_pt="Peripheral swelling" meddra_pt_id="10048959" />
    </Mention>
    <Mention id="M616" len="12" reason="manifestation_or_complication" section="S2" start="1769" type="NonOSE_AE">
      <Normalization meddra_llt="Swelling of leg's soft tissue" meddra_llt_id="10042699" meddra_pt="Peripheral swelling" meddra_pt_id="10048959" />
    </Mention>
    <Mention id="M729" len="15" reason="from_drug_use" section="S3" start="2209" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M709" len="13" reason="from_drug_use" section="S3" start="2286" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Birth defects" meddra_llt_id="10048305" meddra_pt="Congenital anomaly" meddra_pt_id="10010356" />
      <Normalization meddra_pt="Congenital anomaly in offspring" meddra_pt_id="10063726" />
    </Mention>
    <Mention id="M649" len="9" reason="general_term" section="S3" start="2327" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M650" len="9" reason="AE_only_as_instruction" section="S3" start="2574" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M730" len="13" reason="from_drug_use" section="S3" start="2811" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Birth defects" meddra_llt_id="10048305" meddra_pt="Congenital anomaly" meddra_pt_id="10010356" />
      <Normalization meddra_pt="Congenital anomaly in offspring" meddra_pt_id="10063726" />
    </Mention>
    <Mention id="M651" len="9" reason="AE_only_as_instruction" section="S3" start="3651" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M652" len="24" reason="AE_only_as_instruction" section="S3" start="4136" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnancy test negative" meddra_llt_id="10036574" meddra_pt="Pregnancy test negative" meddra_pt_id="10036574" />
    </Mention>
    <Mention id="M627" len="26" reason="preexisting_condition_or_risk_factor" section="S3" start="4472" type="Not_AE_Candidate">
      <Normalization meddra_llt="Irregular menstrual cycle" meddra_llt_id="10022991" meddra_pt="Menstruation irregular" meddra_pt_id="10027339" />
    </Mention>
    <Mention id="M707" len="66" reason="AE_only_as_instruction" section="S3" start="4558" type="NonOSE_AE">
      <Normalization meddra_llt="Paternal drugs affecting fetus" meddra_llt_id="10068445" meddra_pt="Paternal drugs affecting foetus" meddra_pt_id="10050425" />
    </Mention>
    <Mention id="M653" len="17" reason="AE_only_as_instruction" section="S3" start="5276" type="NonOSE_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M654" len="8" reason="AE_only_as_instruction" section="S3" start="5840" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M655" len="9" reason="AE_only_as_instruction" section="S3" start="5870" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M628" len="2" reason="indication" section="S3" start="6458" type="Not_AE_Candidate">
      <Normalization meddra_llt="Multiple myeloma" meddra_llt_id="10028228" meddra_pt="Plasma cell myeloma" meddra_pt_id="10035226" />
    </Mention>
    <Mention id="M710" len="22" reason="from_drug_use" section="S3" start="6493" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M711" len="22" reason="from_drug_use" section="S3" start="6525" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombosis venous deep" meddra_llt_id="10043642" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M731" len="18" reason="from_drug_use" section="S3" start="6552" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary embolism" meddra_llt_id="10037377" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M712" len="22" reason="from_drug_use" section="S3" start="6746" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M732" len="22" reason="from_drug_use" section="S3" start="6921" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ischemic heart disease" meddra_llt_id="10055218" meddra_pt="Myocardial ischaemia" meddra_pt_id="10028600" />
    </Mention>
    <Mention id="M713" len="21" reason="from_drug_use" section="S3" start="6963" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M714" len="6" reason="from_drug_use" section="S3" start="6997" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M733" len="24" reason="from_drug_use" section="S3" start="7005" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Accident cerebrovascular" meddra_llt_id="10000374" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M629" len="2" reason="indication" section="S3" start="7094" type="Not_AE_Candidate">
      <Normalization meddra_llt="Multiple myeloma" meddra_llt_id="10028228" meddra_pt="Plasma cell myeloma" meddra_pt_id="10035226" />
    </Mention>
    <Mention id="M656" len="15" reason="AE_only_as_instruction" section="S3" start="7446" type="NonOSE_AE">
      <Normalization meddra_llt="Thromboembolism" meddra_llt_id="10043566" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M657" len="19" reason="manifestation_or_complication" section="S3" start="7543" type="NonOSE_AE">
      <Normalization meddra_llt="Shortness of breath" meddra_llt_id="10040604" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M658" len="10" reason="manifestation_or_complication" section="S3" start="7564" type="NonOSE_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M659" len="3,8" reason="manifestation_or_complication" section="S3" start="7579,7590" type="NonOSE_AE">
      <Normalization meddra_llt="Swelling arm" meddra_llt_id="10042680" meddra_pt="Peripheral swelling" meddra_pt_id="10048959" />
    </Mention>
    <Mention id="M660" len="12" reason="manifestation_or_complication" section="S3" start="7586" type="NonOSE_AE">
      <Normalization meddra_llt="Swelling of leg's soft tissue" meddra_llt_id="10042699" meddra_pt="Peripheral swelling" meddra_pt_id="10048959" />
    </Mention>
    <Mention id="M661" len="15" reason="AE_only_as_instruction" section="S3" start="7667" type="NonOSE_AE">
      <Normalization meddra_llt="Thromboembolism" meddra_llt_id="10043566" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M630" len="2" reason="indication" section="S3" start="7957" type="Not_AE_Candidate">
      <Normalization meddra_llt="Multiple myeloma" meddra_llt_id="10028228" meddra_pt="Plasma cell myeloma" meddra_pt_id="10035226" />
    </Mention>
    <Mention id="M662" len="9" reason="general_term" section="S3" start="8124" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M631" len="2" reason="indication" section="S3" start="8162" type="Not_AE_Candidate">
      <Normalization meddra_llt="Multiple myeloma" meddra_llt_id="10028228" meddra_pt="Plasma cell myeloma" meddra_pt_id="10035226" />
    </Mention>
    <Mention id="M734" len="10" reason="from_drug_use" section="S3" start="8394" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drowsiness" meddra_llt_id="10013649" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M715" len="10" reason="from_drug_use" section="S3" start="8409" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M663" len="10" reason="general_term" section="S3" start="8477" type="NonOSE_AE">
      <Normalization meddra_llt="Drowsiness" meddra_llt_id="10013649" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M664" len="10" reason="AE_only_as_instruction" section="S3" start="8554" type="NonOSE_AE">
      <Normalization meddra_llt="Drowsiness" meddra_llt_id="10013649" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M665" len="10,13" reason="manifestation_or_complication" section="S3" start="8668,8772" type="NonOSE_AE">
      <Normalization meddra_llt="Impaired driving ability" meddra_llt_id="10049564" meddra_pt="Impaired driving ability" meddra_pt_id="10049564" />
    </Mention>
    <Mention id="M666" len="13,9,9" reason="manifestation_or_complication" section="S3" start="8668,8789,8826" type="NonOSE_AE">
      <Normalization meddra_llt="Impaired ability to use machinery" meddra_llt_id="10077474" meddra_pt="Impaired ability to use machinery" meddra_pt_id="10077474" />
    </Mention>
    <Mention id="M735" len="12" reason="from_drug_use" section="S3" start="8934" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nerve damage" meddra_llt_id="10029177" meddra_pt="Nerve injury" meddra_pt_id="10052897" />
    </Mention>
    <Mention id="M716" len="21" reason="from_drug_use" section="S3" start="8970" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy peripheral" meddra_llt_id="10029331" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M717" len="21" reason="from_drug_use" section="S3" start="9108" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy peripheral" meddra_llt_id="10029331" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M718" len="21" reason="from_drug_use" section="S3" start="9203" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy peripheral" meddra_llt_id="10029331" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M719" len="10" reason="from_drug_use" section="S3" start="9458" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M632" len="3" reason="indication" section="S3" start="9501" type="Not_AE_Candidate">
      <Normalization meddra_llt="Erythema nodosum leprosum" meddra_llt_id="10067479" meddra_pt="Type 2 lepra reaction" meddra_pt_id="10070517" />
    </Mention>
    <Mention id="M667" len="22" reason="AE_only_as_instruction" section="S3" start="9597" type="NonOSE_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M668" len="10" reason="AE_only_as_instruction" section="S3" start="9629" type="NonOSE_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M633" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="9654" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hansen's disease" meddra_llt_id="10019138" meddra_pt="Leprosy" meddra_pt_id="10024229" />
    </Mention>
    <Mention id="M669" len="30" reason="AE_only_as_instruction" section="S3" start="9731" type="NonOSE_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M634" len="3" reason="indication" section="S3" start="9765" type="Not_AE_Candidate">
      <Normalization meddra_llt="Erythema nodosum leprosum" meddra_llt_id="10067479" meddra_pt="Type 2 lepra reaction" meddra_pt_id="10070517" />
    </Mention>
    <Mention id="M670" len="10" reason="AE_only_as_instruction" section="S3" start="9950" type="NonOSE_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M671" len="8,5" reason="manifestation_or_complication" section="S3" start="9976,10010" type="NonOSE_AE">
      <Normalization meddra_llt="Numbness in hand" meddra_llt_id="10049681" meddra_pt="Hypoaesthesia" meddra_pt_id="10020937" />
    </Mention>
    <Mention id="M674" len="8,4" reason="manifestation_or_complication" section="S3" start="9976,10020" type="NonOSE_AE">
      <Normalization meddra_llt="Numbness in feet" meddra_llt_id="10049800" meddra_pt="Hypoaesthesia" meddra_pt_id="10020937" />
    </Mention>
    <Mention id="M672" len="8,5" reason="manifestation_or_complication" section="S3" start="9986,10010" type="NonOSE_AE">
      <Normalization meddra_llt="Tingling feet/hands" meddra_llt_id="10043877" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M675" len="8,4" reason="manifestation_or_complication" section="S3" start="9986,10020" type="NonOSE_AE">
      <Normalization meddra_llt="Tingling feet/hands" meddra_llt_id="10043877" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M673" len="4,5" reason="manifestation_or_complication" section="S3" start="9998,10010" type="NonOSE_AE">
      <Normalization meddra_llt="Hand pain" meddra_llt_id="10019116" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M676" len="4,4" reason="manifestation_or_complication" section="S3" start="9998,10020" type="NonOSE_AE">
      <Normalization meddra_llt="Sore feet" meddra_llt_id="10041358" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M677" len="21" reason="AE_only_as_instruction" section="S3" start="10188" type="NonOSE_AE">
      <Normalization meddra_llt="Neuropathy peripheral" meddra_llt_id="10029331" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M678" len="23" reason="AE_only_as_instruction" section="S3" start="10457" type="NonOSE_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M679" len="10" reason="AE_only_as_instruction" section="S3" start="10659" type="NonOSE_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M680" len="10" reason="AE_only_as_instruction" section="S3" start="10740" type="NonOSE_AE">
      <Normalization meddra_llt="Neuropathy" meddra_llt_id="10029328" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Mention>
    <Mention id="M720" len="9" reason="from_drug_use" section="S3" start="10958" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M721" len="23" reason="from_drug_use" section="S3" start="10972" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Orthostatic hypotension" meddra_llt_id="10031127" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M736" len="33" reason="from_drug_use" section="S3" start="11131" type="OSE_Labeled_AE">
      <Normalization meddra_llt="White blood cell count decreased" meddra_llt_id="10047942" meddra_pt="White blood cell count decreased" meddra_pt_id="10047942" />
    </Mention>
    <Mention id="M722" len="11" reason="from_drug_use" section="S3" start="11176" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M635" len="45" reason="preexisting_condition_or_risk_factor" section="S3" start="11303" type="Not_AE_Candidate">
      <Normalization meddra_llt="Absolute neutrophil count decreased" meddra_llt_id="10059234" meddra_pt="Neutrophil count decreased" meddra_pt_id="10029366" />
    </Mention>
    <Mention id="M636" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="11481" type="Not_AE_Candidate">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M637" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="11519" type="Not_AE_Candidate">
      <Normalization meddra_llt="HIV seropositive NOS" meddra_llt_id="10020183" meddra_pt="HIV test positive" meddra_pt_id="10020188" />
    </Mention>
    <Mention id="M681" len="32" reason="AE_only_as_instruction" section="S3" start="11540" type="NonOSE_AE">
      <Normalization meddra_llt="Absolute neutrophil count decreased" meddra_llt_id="10059234" meddra_pt="Neutrophil count decreased" meddra_pt_id="10029366" />
    </Mention>
    <Mention id="M682" len="11" reason="AE_only_as_instruction" section="S3" start="11662" type="NonOSE_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M723" len="16" reason="from_drug_use" section="S3" start="11797" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M683" len="8" reason="AE_only_as_instruction" section="S3" start="12064" type="NonOSE_AE">
      <Normalization meddra_llt="Bleeding" meddra_llt_id="10005103" meddra_pt="Haemorrhage" meddra_pt_id="10055798" />
    </Mention>
    <Mention id="M644" len="9" reason="manifestation_or_complication" section="S3" start="12083" type="NonOSE_AE">
      <Normalization meddra_llt="Petechiae" meddra_llt_id="10034754" meddra_pt="Petechiae" meddra_pt_id="10034754" />
    </Mention>
    <Mention id="M645" len="9" reason="manifestation_or_complication" section="S3" start="12094" type="NonOSE_AE">
      <Normalization meddra_llt="Epistaxis" meddra_llt_id="10015090" meddra_pt="Epistaxis" meddra_pt_id="10015090" />
    </Mention>
    <Mention id="M646" len="25" reason="manifestation_or_complication" section="S3" start="12109" type="NonOSE_AE">
      <Normalization meddra_llt="Bleeding gastrointestinal" meddra_llt_id="10005116" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M647" len="8" reason="AE_only_as_instruction" section="S3" start="12198" type="NonOSE_AE">
      <Normalization meddra_llt="Bleeding" meddra_llt_id="10005103" meddra_pt="Haemorrhage" meddra_pt_id="10055798" />
    </Mention>
    <Mention id="M638" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="12309" type="Not_AE_Candidate">
      <Normalization meddra_llt="HIV seropositive NOS" meddra_llt_id="10020183" meddra_pt="HIV test positive" meddra_pt_id="10020188" />
    </Mention>
    <Mention id="M737" len="21,8" reason="from_drug_use" section="S3" start="12346,12382" type="OSE_Labeled_AE">
      <Normalization meddra_llt="HIV RNA rebound" meddra_llt_id="10049834" meddra_pt="Blood HIV RNA increased" meddra_pt_id="10049827" />
    </Mention>
    <Mention id="M639" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="12559" type="Not_AE_Candidate">
      <Normalization meddra_llt="HIV seropositive NOS" meddra_llt_id="10020183" meddra_pt="HIV test positive" meddra_pt_id="10020188" />
    </Mention>
    <Mention id="M640" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="12797" type="Not_AE_Candidate">
      <Normalization meddra_llt="HIV seropositive NOS" meddra_llt_id="10020183" meddra_pt="HIV test positive" meddra_pt_id="10020188" />
    </Mention>
    <Mention id="M738" len="11" reason="from_drug_use" section="S3" start="12956" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M724" len="11" reason="from_drug_use" section="S3" start="13032" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M684" len="11" reason="AE_only_as_instruction" section="S3" start="13158" type="NonOSE_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M685" len="11" reason="AE_only_as_instruction" section="S3" start="13258" type="NonOSE_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M686" len="7" reason="manifestation_or_complication" section="S3" start="13274" type="NonOSE_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M687" len="19" reason="AE_only_as_instruction" section="S3" start="13357" type="NonOSE_AE">
      <Normalization meddra_llt="Pulse rate decrease" meddra_llt_id="10037486" meddra_pt="Heart rate decreased" meddra_pt_id="10019301" />
    </Mention>
    <Mention id="M725" len="22" reason="from_drug_use" section="S3" start="13552" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin toxicity" meddra_llt_id="10059516" meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
      <Normalization meddra_pt="Skin reaction" meddra_pt_id="10040914" />
    </Mention>
    <Mention id="M726" len="24" reason="from_drug_use" section="S3" start="13585" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syndrome Stevens-Johnson" meddra_llt_id="10042849" meddra_pt="Stevens-Johnson syndrome" meddra_pt_id="10042033" />
    </Mention>
    <Mention id="M727" len="26" reason="from_drug_use" section="S3" start="13614" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxic epidermal necrolysis" meddra_llt_id="10044223" meddra_pt="Toxic epidermal necrolysis" meddra_pt_id="10044223" />
    </Mention>
    <Mention id="M688" len="5" reason="general_term" section="S3" start="13655" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M689" len="9" reason="AE_only_as_instruction" section="S3" start="13719" type="NonOSE_AE">
      <Normalization meddra_llt="Skin rash" meddra_llt_id="10040913" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M690" len="4,7" reason="AE_only_as_instruction" section="S3" start="13803,13837" type="NonOSE_AE">
      <Normalization meddra_llt="Bullous rash" meddra_llt_id="10006569" meddra_pt="Dermatitis bullous" meddra_pt_id="10012441" />
    </Mention>
    <Mention id="M691" len="4,8" reason="AE_only_as_instruction" section="S3" start="13803,13824" type="NonOSE_AE">
      <Normalization meddra_llt="Rash purpuric" meddra_llt_id="10037887" meddra_pt="Purpura" meddra_pt_id="10037549" />
    </Mention>
    <Mention id="M692" len="4,11" reason="AE_only_as_instruction" section="S3" start="13803,13811" type="NonOSE_AE">
      <Normalization meddra_llt="Exfoliative rash" meddra_llt_id="10064579" meddra_pt="Exfoliative rash" meddra_pt_id="10064579" />
    </Mention>
    <Mention id="M693" len="24" reason="AE_only_as_instruction" section="S3" start="13851" type="NonOSE_AE">
      <Normalization meddra_llt="Syndrome Stevens-Johnson" meddra_llt_id="10042849" meddra_pt="Stevens-Johnson syndrome" meddra_pt_id="10042033" />
    </Mention>
    <Mention id="M694" len="26" reason="AE_only_as_instruction" section="S3" start="13879" type="NonOSE_AE">
      <Normalization meddra_llt="Toxic epidermal necrolysis" meddra_llt_id="10044223" meddra_pt="Toxic epidermal necrolysis" meddra_pt_id="10044223" />
    </Mention>
    <Mention id="M728" len="8" reason="from_drug_use" section="S3" start="14050" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M739" len="21" reason="from_drug_use" section="S3" start="14070" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Convulsions grand mal" meddra_llt_id="10010918" meddra_pt="Generalised tonic-clonic seizure" meddra_pt_id="10018100" />
    </Mention>
    <Mention id="M695" len="7" reason="AE_only_as_instruction" section="S3" start="14353" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M696" len="13" reason="AE_only_as_instruction" section="S3" start="14429" type="NonOSE_AE">
      <Normalization meddra_llt="Convulsive threshold lowered" meddra_llt_id="10010927" meddra_pt="Convulsive threshold lowered" meddra_pt_id="10010927" />
    </Mention>
    <Mention id="M641" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="14514" type="Not_AE_Candidate">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M697" len="8" reason="AE_only_as_instruction" section="S3" start="14573" type="NonOSE_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M698" len="7" reason="AE_only_as_instruction" section="S3" start="14660" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M740" len="20" reason="from_drug_use" section="S3" start="14688" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tumor lysis syndrome" meddra_llt_id="10045152" meddra_pt="Tumour lysis syndrome" meddra_pt_id="10045170" />
    </Mention>
    <Mention id="M648" len="20" reason="AE_only_as_instruction" section="S3" start="14740" type="NonOSE_AE">
      <Normalization meddra_llt="Tumor lysis syndrome" meddra_llt_id="10045152" meddra_pt="Tumour lysis syndrome" meddra_pt_id="10045170" />
    </Mention>
    <Mention id="M642" len="5" reason="preexisting_condition_or_risk_factor" section="S3" start="14787" type="Not_AE_Candidate">
      <Normalization meddra_llt="Neoplasm" meddra_llt_id="10028980" meddra_pt="Neoplasm" meddra_pt_id="10028980" />
    </Mention>
    <Mention id="M699" len="11" reason="AE_only_as_instruction" section="S3" start="15081" type="NonOSE_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M700" len="16" reason="AE_only_as_instruction" section="S3" start="15100" type="NonOSE_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M701" len="9" reason="AE_from_drug_interaction" section="S3" start="15233" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M702" len="8" reason="AE_from_drug_interaction" section="S3" start="15246" type="NonOSE_AE">
      <Normalization meddra_llt="Bleeding" meddra_llt_id="10005103" meddra_pt="Haemorrhage" meddra_pt_id="10055798" />
    </Mention>
    <Mention id="M643" len="10" reason="preexisting_condition_or_risk_factor" section="S3" start="15354" type="Not_AE_Candidate">
      <Normalization meddra_llt="Neoplasm malignant" meddra_llt_id="10028997" meddra_pt="Neoplasm malignant" meddra_pt_id="10028997" />
    </Mention>
    <Mention id="M741" len="15" reason="from_drug_use" section="S3" start="15447" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thromboembolism" meddra_llt_id="10043566" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M703" len="15" reason="AE_only_as_instruction" section="S3" start="15498" type="NonOSE_AE">
      <Normalization meddra_llt="Thromboembolism" meddra_llt_id="10043566" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M742" len="16" reason="from_drug_use" section="S3" start="15644" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M708" len="25" reason="manifestation_or_complication" section="S3" start="15743" type="NonOSE_AE">
      <Normalization meddra_llt="Rash macular" meddra_llt_id="10037867" meddra_pt="Rash macular" meddra_pt_id="10037867" />
    </Mention>
    <Mention id="M704" len="5" reason="manifestation_or_complication" section="S3" start="15795" type="NonOSE_AE">
      <Normalization meddra_llt="Fever" meddra_llt_id="10016558" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M705" len="11" reason="manifestation_or_complication" section="S3" start="15802" type="NonOSE_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M706" len="11" reason="manifestation_or_complication" section="S3" start="15819" type="NonOSE_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
  </Mentions>
</GoldLabel>